




A comparison of MDMA (Ecstasy) and 3,4-methylenedioxymethcathinone 
(Methylone) in their acute behavioural effects and development of tolerance in 
rats 
 
A thesis submitted in partial fulfilment of the requirements for the Degree 
of Master of Science in Psychology 
 
 
Mark L Davidson 
 
Supervised by 
Professor Robert N Hughes 
 
  














1.1 Background…………………………………………………………………….. 4 
1.2 MDMA……………………………………………………………………......... 5 
1.2.1 Psychopharmacology of MDMA…………………………………... 6 
1.2.2 Acute behavioural effects of MDMA in human users....................... 9 
1.3 Methylone……………………………………………………………………… 11 
1.3.1 Psychopharmacology of methylone………………………………... 12 
1.3.2 Acute behavioural effects of methylone in human users…………... 15 
1.4 Animal Studies…………………………………………………………………. 15 
1.4.1 Acute behavioural effects of MDMA……………………………… 15 
1.4.2 Acute behavioural effects of methylone…………………………… 28 
1.5 Effect of Repeated Drug Exposure…………………………………………….. 29 
1.6 Adverse Effects and Hyperthermia…………………………………………….. 33 
1.7 Behavioural Tests Used in the Current Study………………………………….. 36 
1.8 Rationale and Hypotheses……………………………………………………… 39 
2.0 Method 
2.1 Animals………………………………………………………………………… 42 
2.2 Drugs…………………………………………………………………………… 42 
2.3 Procedure………………………………………………………………………..43 
2.3.1 Procedure for the acute behavioural effects of MDMA and 
methylone…………………………………………………………... 43 
2.3.2 Procedure for repeated drug exposure………………………………47 
2.4 Statistical Analysis……………………………………………………………... 48 
3.0 Results 
3.1 Acute Behavioural Effects of MDMA and Methylone………………………….49 
3.1.1 Open field test……………………………………………………….49 
3.1.2 Light/Dark box……………………………………………………... 55 
3.1.3 Novel object recognition task……………………………………….59 
3.2 Temperature Change with Repeated Drug Administration……………………..64 
3.3 Unexpected Deaths and LD50…………………………………………………..65 
3.4 Behavioural Testing Following Repeated Drug Exposure…………………….. 66 
3.4.1 Open field test……………………………………………………… 66 
3.4.2 Light/Dark box……………………………………………………... 68 
4.0 Discussion 
4.1 General Summary…………………………………………………………….….71 
4.2 The Acute Behavioural Effects of MDMA and Methylone………………….….72 
4.2.1 Locomotor activity……………………………………………….….73 
4.2.2 Rearing activity……………………………………………………...77 
4.2.3 Light/Dark box and anxiety……………………………………….…80 
4.2.4 Memory………………………………………………………….…..84 
4.3 Repeated Drug Exposure…………………………………………………….…..86 
4.3.1 Open field test………………………………………………………..86 
4.3.2 Rearing activity……………………………………………………....88 
4.3.3 Light/Dark box test…………………………………………………..89 
4.4 Temperature, Toxicity, and Rat Strain…………………………………………...91 
4.5 Implications of the Current Findings………………………………………...…..93 
4.5.1 Addiction……………………………………………………………..93 
4.5.2 Safety and toxicity……………………………………………………94 
4.5.3 Sex differences……………………………………………………….95 
4.5.4 Anxiety……………………………………………………………….97 
4.5.5 Memory……………………………………………………………....97 
4.6 Limitations of the Current Study…………………………………………………98 








List of Figures 
 
Figure 1.1. Chemical structure of methylone and MDMA………………………………13 
Figure 1.2. Locomotor paths of rats……………………………………………………...18 
Figure 2.1. Aerial view of the open field with spatial location parameters……………...44 
Figure 3.1. Mean (± SEM) displacement in the open field………………………………52 
Figure 3.2. Mean (± SEM) time spent in the centre of the open field……………………53 
Figure 3.3. Mean (± SEM) number of rearings in the open field………………………...54 
Figure 3.4. Mean (± SEM) time spent in the light compartment of the Light/Dark 
Box.................................................................................................................. 57 
Figure 3.5. Mean (± SEM) number of transitions between the light and dark 
compartments of the Light/Dark Box………………………………………..58 
Figure 3.6. Mean (± SEM) emergence latency from the dark side of the Light/Dark 
Box…………………………………………………………………………...59 
Figure 3.7. Mean (± SEM) total exploration time of objects in the Novel Object 
Recognition task……………………………………………………………...62 
Figure 3.8. Mean (± SEM) total exploration time of objects in the Novel Object 
Recognition task for each sex averaged across drug type……………………62 
Figure 3.9. Mean (± SEM) discrimination index in the Novel Object Recognition 
task…………………………………………………………………………...63 
Figure 3.10. Mean (± SEM) temperature of rats during repeated administration                  
of MDMA, methylone, or saline …………………………………………….65 
Figure 3.11. Mean (± SEM) time spent in the light side of the Light/Dark Box before      
and after repeated exposure to drug or saline ………………………………..69 
Figure 3.12. Mean (± SEM) number of transitions in the Light/Dark Box before and        






List of Tables 
 
Table 1.1. Summary of animal studies examining the effect of MDMA on exploratory 
activity………………………………………………………………………..22 
Table 1.2. Summary of animal studies examining the effect of MDMA on anxiety……25 
Table 3.1. Means and Standard Deviations of Open Field Responses with T-tests 
Between the Means of all MDMA and all Methylone Groups Collapsed         
for Each Test…………………………………………………………………50 
Table 3.2. Means and Standard Deviations of Light/Dark Box parameters with                
T-tests Between the Means of all MDMA and all Methylone Groups 
Collapsed for Each Test……………………………………………………...56 
Table 3.3. Means and Standard Deviations of Novel Object Recognition Task   
parameters with T-tests Between the Means of all MDMA and all            
Methylone Groups Collapsed for Each Test…………………………………60 
Table 3.4. Means and Standard Deviations of Temperatures of Rats During                   
and After Repeated Administration of Saline, MDMA, or Methylone………64 



















I wish to thank everyone who made this thesis possible. Firstly, I would like to sincerely thank 
my supervisor, Rob Hughes. Your knowledge and constant feedback was invaluable, and your 
patience in allowing me to put this work on hold for 4 years to complete a medical degree was 
much appreciated. I would also like to thank Neroli Harris and Silvana De Freitas for their 
valuable assistance in the animal lab, and for taking thoughtful care of the animals. A big thank 
you to all of my friends, both in psychology and in Sydney for your support and for helping 
me to take much needed breaks away from work. Finally to my family and my partner Rinz, 







5-HT  Serotonin 
ANOVA Analysis of Variance 
C  Celsius 
cm  Centimetres 
DMTS  Delayed matching to sample 
EPM  Elevated plus maze 
h  Hours 
i.p.  Intraperitoneal 
LDB  Light/Dark box 
MDMA 3, 4-methylenedioxymethamphatemine 
Methylone 3,4-methylenedioxymethcathinone 
mg  Milligrams 
mg/kg  Milligrams per kilogram 
DA  Dopamine 
DAT  Dopamine transporter 
DN  Drug-naïve 
DT  Drug-treated 
NA  Noradrenaline 
NAcc  Nucleus accumbens 
NAT  Noradrenaline transporter 
NOR  Novel object recognition 
SEM  Standard error of the mean 







Methylone (3,4-methylenedioxymethcathinone), the -ketone analogue of the popular party 
drug MDMA (3,4-methylenedioxymethamphetamine, “ecstasy”), is a relatively new designer 
drug that is reported to have similar subjective effects and psychopharmacological properties 
to MDMA. However, unlike MDMA, little is known about the acute behavioural effects or the 
effects of repeated use of this drug. The goal of the current thesis was to investigate the 
behavioural effects of methylone and compare these to the effects of MDMA using an animal 
model. The second aim was to determine whether there was evidence of behavioural 
sensitisation or tolerance to methylone with repeated exposure. To achieve this, 108 male and 
female PVG/c hooded rats (6M and 6F per group) were administered various doses of MDMA 
or methylone (2.5, 5, 8, 12mg/kg), or saline vehicle (i.p.). The behavioural effects of these 
drugs were examined 20 m later, including horizontal locomotor activity, rearing behaviour, 
and central occupancy of an open field, anxiety behaviours in a light/dark box, and working 
memory in a novel object recognition task. The results showed that MDMA and methylone 
administration produce similar, but not identical, behaviours. Methylone was shown to produce 
greater psychostimulant effects, while MDMA produced more toxic effects. Female rats 
demonstrated greater psychostimulant effects than males, while males had higher rates of 
lethality. In order to assess the effects of repeated drug use, one week after binge-type drug 
administration of MDMA or methylone (5 mg/kg for 3 doses every 1h on 2 consecutive days), 
open field and light/dark box testing was repeated following a further 5 mg/kg challenge of 
drug. There was no evidence of locomotor sensitisation in the open field, although females 
showed sensitisation in rearing activity. These findings suggest that methylone may produce 
less toxic, but more stimulant, effects than MDMA. Methylone may therefore be a cocaine-





MDMA (3,4-methylenedioxymethamphetamine), known by the street name “ecstasy”, 
is an illegal party drug that is known to produce a range of pleasant effects in users including 
euphoria, energy, empathy, and warmth towards others. Ever since being classified as an illegal 
substance people have been searching for non-scheduled alternatives with similar 
psychopharmacological effects (Bossong, Van Dijk, & Niesink, 2005). The use of novel 
synthetic psychoactive substances has therefore been increasing worldwide in recent years 
(Palamar, Martins, Su, & Ompad, 2015). For example, by 2013 the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) had reported the occurrence of over 200 
new psychoactive substances in Europe, with new compounds being added every week 
(Iversen, White, & Treble, 2014). These drugs tend to be synthetic analogues of other illicit 
compounds, such as MDMA or N-substituted piperazines, and are often created to mimic these 
drugs while evading law enforcement. These substances are sold on the internet and smart 
shops under guises such as “bath salts” or “plant food”, with a warning that they are not for 
human consumption, in order to conceal their use as drugs (P. S. Johnson & Johnson, 2014). 
One of the more prevalent of these novel psychoactive substances is the synthetic 
cathinone “methylone” (2-methylamino-1-[3,4-methylenedioxyphenyl]propan-1-one, bk-
MDMA), which is the -ketone analogue of MDMA (Lopez-Arnau et al., 2013). Cathinone is 
a naturally occurring beta-ketoamphetamine analogue found in the leaves of the Catha edulis 
(Khat) plant. The synthetic cathinones are derivatives of this substance and are amongst the 
most common constituents of “bath salts”; a diverse group of designer drugs in the 
phenethylamine chemical class (Palamar, 2015). Since the subjective effects of methylone and 
other synthetic cathinones are said to be similar to other amphetamine derivatives, the use of 
these substances has been increasing rapidly worldwide as legal alternatives (Brunt et al., 2016; 
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Yin & Ho, 2012). While recreational doses enhance mood and increase alertness, higher doses 
have been associated with numerous adverse health outcomes (Lehner & Baumann, 2013). For 
example, in the US in 2011 there were over 20,000 emergency depatment visits and 6,137 
poisonings from the use of “bath salts” (Palamar, Salomone, Vincenti, & Cleland, 2016). 
Owing to the public health risks imposed, methylone and several related compounds 
were temporarily classified as Schedule I in the US by the DEA in October 2011. Methylone 
was extended into this schedule permanently in 2013 (Lehner & Baumann, 2013; Lopez-Arnau 
et al., 2013). In New Zealand, methylone is not specifically scheduled in the Misuse of Drugs 
Act 1975, however it is considered to be an amphetamine analogue, and is therefore a Class C 
prohibited substance.  
While much is known about the acute and chronic effects of MDMA use, very little is 
known about the behavioural effects of methylone. This will be the topic of the current enquiry. 
 
1.2 MDMA 
MDMA is a substituted phenethylamine which is structurally similar to 
methamphetamine and mescaline. It was first synthesised and patented in 1912 by the 
pharmaceutical company Merck as a precursor in a new chemical pathway in the synthesis of 
a clotting agent “hydrastinine”, however basic toxicological and pharmacological testing was 
not conducted until years later (Freudenmann, Oxler, & Bernschneider-Reif, 2006). 
Interestingly, the first formal studies on toxicology and behavioural pharmacology in animals 
were conducted at the University of Michigan in 1953-54 by the US army, and were therefore 
classified until 1969 (Shulgin, 1986).  
Some of the earliest reports of the psychopharmacological effects in humans come from 
research studies by Alexander Shulgin, finding that MDMA induces an easily controlled state 
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of altered consciousness (Shulgin, 1986). Soon after, a number of behavioural studies were 
undertaken which showed that MDMA acted as an analgesic and CNS stimulant in mice 
(Braun, Shulgin, & Braun, 1980). Toxicological studies in animals at substantially lethal doses 
found that MDMA caused a spectrum of behaviour including tremors, salivation, emesis, and 
death in a number of animals. 
MDMA was classified as a Schedule 1 substance by the DEA in the US in 1985 on the 
grounds that it was a potential neurotoxin and due to the opinion that MDMA had no accepted 
medical use and high abuse potential (Cole & Sumnall, 2003a). In New Zealand, MDMA is 
currently classified as a Schedule 2 Class B controlled substance. 
Despite being outlawed in the mid-1980s MDMA continues to maintain widespread 
popularity, particularly amongst young adults. In NZ, in a national household survey of people 
between 15 and 45 years old, it was found that the self-reported use of ecstasy in the last year 
had increased significantly from 1.5% in 1998 to 3.9% in 2006 (Wilkins & Sweetsur, 2008). 
In the US in 2008, 12.8% of young adults aged 18 to 25 years in a nationally representative 
sample reported lifetime MDMA use, with rates of use much higher in the subset of the 
population that attend raves or other electronic dance music (EDM) events (Palamar et al., 
2016). 
1.2.1 Psychopharmacology of MDMA. 
Amphetamine derivatives, such as MDMA, act by enhancing release of central 
monoamine neurotransmitters (Cozzi, Sievert, Shulgin, Jacob, & Ruoho, 1999; Gudelsky & 
Yamamoto, 2008; Rothman & Baumann, 2003), and it has been extensively demonstrated that 
both serotonergic and dopaminergic mechanisms are responsible for the unique behavioural 
effects of MDMA (Gudelsky & Yamamoto, 2008). 
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The increased extracellular monoamine concentrations have been shown to occur 
through two distinct mechanisms (Cozzi et al., 1999). The first mechanism is through reduced 
uptake of released monoamines by inhibition of their specific transporters. There are 
transporter proteins expressed by serotonergic (SERT), dopaminergic (DAT) and 
noradrenergic (NAT) neurons whose function is to uptake released monoamine 
neurotransmitters from the synaptic cleft back into the neuron after release. This is the principle 
mechanism for inactivation of monoamine signalling (Rothman & Baumann, 2003). MDMA 
has been shown to potently block all three monoamine transporters causing a reduction in 
uptake after they are released and increased action of these neurotransmitters on their target 
receptors (Iravani, Asari, Patel, Wieczorek, & Kruk, 2000; Nagai, Nonaka, & Satoh Hisashi 
Kamimura, 2007; Steele, Nichols, & Yim, 1987). The second mechanism involves MDMA 
acting as a competing substrate at these transporter proteins where it enters the nerve ending 
via substrate specific carrier-mediated transport (Crespi, Mennini, & Gobbi, 1997). Once inside 
it has two effects which result in increased efflux of monoamine neurotransmitters. Firstly, it 
causes neurotransmitter release from intracellular storage vesicles resulting in an increase in 
cytoplasmic concentrations available for release. Secondly, it promotes neurotransmitter 
release through a process of transporter-mediated exchange by the monoamine transport 
proteins (Crespi et al., 1997; Rothman & Baumann, 2003; Rudnick & Wall, 1992; Sulzer et al., 
1995). MDMA is therefore an indirect agonist of serotonin (5-HT), dopamine (DA), and 
noradrenaline (NA), inducing release of these monoamines from nerve terminals via 
transporter dependent mechanisms (Rothman & Baumann, 2003; Rudnick & Wall, 1992; 
Scearce-Levie, Viswanathan, & Hen, 1999). 
MDMA is by far a more potent releaser of 5-HT than DA or NA (Schmidt & Kehne, 
1990). It has been shown that the most characteristic acute effect of MDMA in animals is rapid 
release of 5-HT from presynaptic vesicles and serotonin reuptake inhibition (Crespi et al., 1997; 
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Iravani et al., 2000), with a dose-dependent increase in concentrations of 5-HT in the striatum, 
hippocampus, and cortex (Gough, Ali, Slikker, & Holson, 1991; Gudelsky & Nash, 1996). By 
6 hours post administration there is a decline in the behavioural effects of MDMA as 5-HT 
efflux ceases, followed by a gradual recovery of 5-HT levels over the next 24 hours (Schmidt, 
Levin, & Lovenberg, 1987). 
The effects of MDMA on the dopaminergic system are less pronounced, a property 
which separates MDMA greatly from other amphetamines, which have very potent effects on 
dopamine release (Gazzara, Takeda, Cho, & Howard, 1989; Spanos & Yamamoto, 1989). 
MDMA has been shown to stimulate the release of DA and block the reuptake of DA into brain 
synaptosomes (M. P. Johnson, Hoffman, & Nichols, 1986; M. P. Johnson, Huang, & Nichols, 
1991; Schmidt et al., 1987; Spanos & Yamamoto, 1989; Steele et al., 1987). Activation of the 
5-HT2A receptor has been shown to increase dopamine synthesis and release, suggesting that 
DA release may be, at least partly, due to 5-HT release (Gudelsky, Yamamoto, & Nash, 1994). 
It is likely that this DA release is related to the mild euphoria and rewarding properties of 
MDMA (Gudelsky & Yamamoto, 2008). 
Further experiments found similar releasing effects on NA (Rothman et al., 2001). 
Increased levels of NA are not known to correlate with the intoxicant effects of the drug, but it 
is likely to contribute to the sympathomimetic effects via activation of adrenergic receptors, 
resulting in potentially dangerous cardiovascular side-effects, such as increased blood pressure 
(Iversen et al., 2014; Vollenweider, Liechti, Gamma, Greer, & Geyer, 2002). Finally, MDMA 
has been shown to release Ach  (Acquas et al., 2001), although this is to a much lesser degree 
than 5-HT release. This is likely due to direct activation of histamine 1 (H1) receptors 




1.2.1 Acute behavioural effects of MDMA in human users. 
Subjective effects. 
The chemical structure of MDMA is similar to both amphetamine stimulants and 
hallucinogens, however the behavioural pharmacology of this compound is distinct from both 
of these broad drug classes (Fantegrossi, 2008). Human users of MDMA report subjective 
effects including euphoria, altered time perception, increased alertness, luminescence of 
objects, decreased hostility, and powerful feelings of closeness and empathy towards others. 
Negative effects included nausea, insomnia, bruxism, dry mouth, diaphoresis, palpitations, 
tremor, and increased body temperature (Palenicek, Votava, Bubenikova, & Horacek, 2005; 
M. Tancer & Johanson, 2003). The term ‘entactogen’ has been proposed to describe the effects 
of MDMA, literally meaning “producing a touching within”, which refers to the drugs ability 
to allow therapists and patients to access and deal with repressed painful emotional issues (Cole 
& Sumnall, 2003a; Nichols, 1986). Although the hallucinogenic properties of MDMA are 
considered to be weak, some users have reported hallucinogenic effects at higher doses 
(Solowij, Hall, & Lee, 1992). 
Many of the anecdotal reports of the subjective effects of MDMA are hindered by the fact that 
‘ecstasy’ tablets often do not solely contain the active compound MDMA, but may include a 
range of other psychoactive compounds, such as amphetamine, ketamine, or ephedrine (Cole 
and Sumnall, 2003). Subjective effects of MDMA have therefore been extensively investigated 
in controlled laboratory settings using various scales, including the POMS (Profile Of Mood 
States), VAS (Visual Analog Scale), HRS (Hallucinogen Rating Scale), and SDEQ (Subjective 
Drug Effects Questionnaire); e.g. (Cami et al., 2000; Harris, Baggott, Mendelson, Mendelson, 
& Jones, 2002; Kuypers & Ramaekers, 2005; M. E. Tancer & Johanson, 2001).  
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Reported effects have been recorded to peak at 75 to 120 minutes after consumption, 
last two to twelve hours, and include mostly positive effects on mood ratings with a state of 
enhanced mood and well-being (Baylen & Rosenberg, 2006; Vollenweider, Gamma, Liechti, 
& Huber, 1998). Positive effects include excitement, clearer thinking, affection or closeness to 
others, confidence, euphoria, elation, vigour, peacefulness, and relaxation. In contrast, negative 
emotional effects appear to have lower prevalence rates and tend to be associated with higher 
doses. These acute effects include autonomic hyperactivity, anxiety, restlessness, and 
confusion (Baylen & Rosenberg, 2006; de Sousa Fernandes Perna et al., 2014; Downing, 1986; 
Harris et al., 2002; M. E. Tancer & Johanson, 2001; Vollenweider et al., 1998). Somatic effects 
include teeth clenching, temperature changes, nausea, reduced appetite, tremors, mydriasis, and 
sweating (Baylen & Rosenberg, 2006; Downing, 1986; Vollenweider et al., 1998). Some of the 
somatic effects of acute intoxication were present 24 hours post ingestion, such as restlessness, 
suppressed appetite, bruxism, and difficulty concentrating, while new after effects were evident 
in some subjects, including lack of energy and insomnia (Vollenweider et al., 1998). Women 
tended to show stronger responses to MDMA than men, with significantly higher ratings for 
positive mood, anxiety, and somatic effects (Liechti, Gamma, & Vollenweider, 2001). 
Neurocognitive effects. 
Acute intoxication with MDMA has been shown to cause impairment in memory. This 
has been demonstrated in a number of studies on human participants using single MDMA 
doses, with MDMA induced impairment of immediate and delayed recall for both verbal and 
spatial information (Kuypers, de la Torre, Farre, Pujadas, & Ramaekers, 2013; Kuypers & 
Ramaekers, 2005, 2007; Stough et al., 2012; van Wel et al., 2011). Kuypers and Ramaekers 
(2005) tested the effect of a single moderate dose of MDMA (75 mg) on memory functioning 
in MDMA users in a double blind placebo-controlled crossover design. The neurocognitive 
assessments included a verbal word learning task with immediate recall (learning/working 
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memory) and delayed recognition (long term/episodic memory), a syntactic reasoning task 
(working memory and speed), and a digit symbol substitution task (short term memory). They 
found that MDMA impaired working memory during intoxication as assessed by the number 
of words immediately recalled in the word learning task, as well as an impairment in delayed 
recall after 30 minutes, with no residual deficit in memory function after a 24 hour withdrawal 
phase. This suggests that acute intoxication of MDMA causes an impairment in working 
memory, but does not produce a permanent memory deficit from a single dose. Impaired 
working memory during acute MDMA intoxication has also been reported using other 
cognitive performance tasks (de Sousa Fernandes Perna et al., 2014; Stough et al., 2012; van 
Wel et al., 2011). In addition, an impairment of spatial memory for location has been 
demonstrated in acute MDMA intoxication using a spatial memory task (Kuypers & 
Ramaekers, 2007; van Wel et al., 2011).  
Taken together, these results suggest that acute MDMA intoxication may produce 
reversible memory impairments in working and spatial memory. However, studies 
investigating the acute effects of MDMA on working memory and learning tasks have in 
general failed to test for non-mnemonic causes of memory impairment, such as increased 
distraction from non-task related events or stimuli, poorer concentration, or impaired 
psychomotor performance. Indeed, participants in such studies have previously suggested that 
impairments in their performance may have been due to more general problems in attending to 
the relevant task (Kay, Harper, & Hunt, 2010; Parrott & Lasky, 1998). Therefore, whether there 
is an impairment of memory storage or a more general impairment in cognitive processes in 





Methylone was first synthesised and named by Alexander Shulgin while researching 
the effects of betaketone modification of amphetamines. However it was not until years later, 
in 2004, that it began to appear in the Netherlands as a new designer drug called ‘Explosion’ 
(Bossong et al., 2005). It was advertised as a vanilla-scented room odouriser in plastic tubes 
containing 5mL of liquid, and contained the instructions ‘Do not ingest’ in order to circumvent 
Dutch regulations for psychoactive substances (Bossong et al., 2005). In New Zealand, 
methylone was sold legally as an MDMA substitute under the brand name “Ease”. It was 
withdrawn from public supply in April 2006 due to the opinion that it was an amphetamine 
analogue, and is therefore considered a Class C substance. 
Over the past few years methylone has become one of the main constituents of “bath 
salts” and one of the most frequently abused synthetic cathinones in the US (German, 
Fleckenstein, & Hanson, 2014). These substances are most frequently insufflated, although 
many users take them orally in tablet form or dissolved in beverages, rectally, or parenterally 
(German et al., 2014; Karila, Billieux, Benyamina, Lancon, & Cottencin, 2016). 
1.3.1 Psychopharmacology of methylone. 
Chemically, methylone is the -ketone analogue of MDMA, differing by the addition 






              
                   Methylone                                                                    MDMA 
Figure 1.1. Chemical structure of methylone (3,4-methylenedioxymethcathinone) and MDMA (3,4-
methylenedioxymethamphetamine). 
 
The differences in the behavioural effects of psychostimulants have been shown to 
reflect the relative changes in extracellular monoamine concentrations (Iversen et al., 2014). 
This is also likely to be an important mechanism for the behavioural effects of the synthetic 
cathinones (Gatch, Taylor, & Forster, 2013). Since methylone has been reported as having 
similar subjective effects to MDMA, and shares a similar chemical structure, these two 
substances should produce a similar pharmacological profile at monoamine plasma membrane 
transporters. Indeed, several studies examining the neurobiological effects of methylone 
support this rationale. 
Methylone is a potent uptake inhibitor of all three monoamines as well as a substrate 
for all three monoamine transporters. Simmler et al. (2013) determined the potencies of several 
cathinones to inhibit DA, NA, and 5-HT transport in HEK 293 cells expressing human 
monoamine transporters in vitro, as well as their ability to promote DAT and SERT-mediated 
DA and 5-HT efflux. They found that both MDMA and methylone blocked all three 
monoamine transporters. MDMA blocked SERT significantly more than DAT, whereas 
methylone was similar to cocaine and methamphetamine with higher DAT selectivity than 
SERT but with much less potency (Simmler et al., 2013). In a study examining inhibition of 
monoamine uptake transporters in human platelet cells, Cozzi et al. (1999) found that 
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methylone was as potent as MDMA at inhibiting DA and NA reuptake, but three-fold less 
potent than MDMA at inhibiting serotonin reuptake in vitro (Cozzi et al., 1999). This was 
consistent with other research using rat brain synaptosomes (Baumann et al., 2012; Nagai et 
al., 2007). NAT inhibition was more potent than DAT and SERT inhibition for both MDMA 
and methylone (Nagai et al., 2007). 
In addition to blocking reuptake, methylone functions as a substrate for monoamine 
transporters in vitro, stimulating the release of DA and 5-HT by reversal of the normal 
transporter efflux (Baumann et al., 2012; Simmler et al., 2013). Methylone was similar to 
MDMA in its substrate activity, with greater efflux of 5-HT than DA, although the potency of 
methylone was lower. Methylone has been shown to be half as effective as MDMA at 
increasing DA release and one-third as effective as MDMA at increasing 5-HT release (Nagai 
et al., 2007; Sogawa et al., 2011). The addition of the -ketone to MDMA appears, therefore, 
to increase the compounds selectivity for the DAT than SERT and reduce its overall potency. 
The relative effects of a drug on the DAT and SERT are useful to predict the drugs 
characteristics in vivo (Simmler et al., 2013). 
The in vivo neurochemical actions of methylone produced elevations in DA and 5-HT 
which were quantitatively similar to the effects of MDMA with preferential effect on 5-HT, 
but again with less potency. This adds support to the idea that methylone is closer in 
neurochemical effects to MDMA than cocaine or amphetamines (Baumann et al., 2012), 
although its ability to release 5-HT is diminished relative to DA. Because 5-HT release 
dampens the stimulant effects of amphetamine-like drugs, we would expect that methylone 
would have more stimulant-like effects when compared to MDMA (Baumann et al., 2012; 
Simmler et al., 2013). Methylone may also be associated with increased risk of addiction than 
MDMA because of its higher relative action on the DA system. Given this profile of effects on 
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monoamine transporters, it has been suggested that this compound is a cocaine-MDMA-mixed 
cathinone, and may therefore demonstrate behavioural effects similar to both MDMA and 
cocaine (Simmler et al., 2013). 
1.3.2 Acute behavioural effects of methylone in human users. 
While the number of studies on the effects of methylone is humans scant within the 
scientific literature, anecdotal reports suggest that it shares similar subjective effects with 
MDMA, as expected from the pharmacology of this drug (Bossong et al., 2005). Human users 
of methylone have reported via consumer websites that methylone provides entactogenic 
effects but with a calmer euphoria and milder stimulation than that experienced from MDMA 
(Shimizu et al., 2007). Shulgin wrote ‘methylone has almost the same potency as MDMA, but 
it does not produce the same effects. It has almost antidepressant action, pleasant and positive, 
but not the unique magic of MDMA’ (Bossong et al., 2005). 
Despite its widespread use, no studies currently exist that have characterised the 
subjective or neurocognitive effects of methylone in humans in a controlled setting. 
 
1.4 Animal Studies 
1.4.1 Acute behavioural effects of MDMA. 
Numerous studies exist investigating the acute and long-term behavioural effects of 
MDMA in animals (Cole & Sumnall, 2003b). These studies have largely focussed on 
locomotor activity, anxiety, social behaviour, exploratory behaviour, memory, and reward and 
reinforcement. In animals acute administration of MDMA produces neural excitability with 
hyperthermia, hyperactivity, low body posture, salivation, piloerection, ataxia, and mydriasis 
(Spanos & Yamamoto, 1989). The current study will examine the effect of MDMA 
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administration in the rat on several behavioural outcomes including locomotor activity, 
exploratory behaviours, anxiety, and memory. The current literature regarding the acute effects 
of MDMA on these behaviours is summarised below. 
Locomotor activity. 
Animal models of locomotor behaviour provide us with an understanding of the 
complex interactions between neurochemical systems and the behavioural effects of drugs of 
abuse, particularly the stimulants and hallucinogens (Risbrough et al., 2006). The 
characterisation and quantification of locomotor paths and investigatory behaviours has 
demonstrated unique behavioural patterns for the psychostimulant drugs, leading to a greater 
understanding of their pharmacological mechanisms (Paulus & Geyer, 1992; Risbrough et al., 
2006). 
Administration of MDMA has been shown to dose-dependently (0 to 20 mg/kg) 
increase horizontal locomotor activity in the open field test in rats (Callaway, Johnson, Gold, 
Nichols, & Geyer, 1991; Callaway, Wing, & Geyer, 1990; Herin, Liu, Ullrich, Rice, & 
Cunningham, 2005; Kehne et al., 1996; Spanos & Yamamoto, 1989), with females 
demonstrating a higher sensitivity to the stimulating effects of MDMA than males (Palenicek 
et al., 2005). While the interplay of neurotransmitter systems and receptors involved is not yet 
fully understood, it has been consistently shown that MDMA induces locomotor hyperactivity 
through indirect actions on both DA and 5-HT systems (Bubar, Pack, Frankel, & Cunningham, 
2004; Callaway et al., 1990; Gold, Hubner, & Koob, 1989; McCreary, Bankson, & 
Cunningham, 1999).  
The locomotor activating effect of MDMA is distinct from other amphetamines since 
the initiating event seems to be activation of serotonergic receptors, particularly 5-HT1B 
(Bankson & Cunningham, 2002; McCreary et al., 1999; Rempel, Callaway, & Geyer, 1993). 
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This is based on the observation that 5-HT1B receptor agonists produce a behavioural profile 
similar to MDMA, with almost identical spatial patterns of locomotion (Bankson & 
Cunningham, 2002; Rempel et al., 1993). In addition, the highly selective 5-HT1B antagonist 
GR127935 significantly and dose-dependently attenuated the locomotor stimulatory effects of 
MDMA in both Sprague-Dawley and Wistar rats back to the level of controls (McCreary et al., 
1999; Steed, Jones, & McCreary, 2011). At higher doses MDMA-stimulated locomotion is 
augmented by 5-HT2A receptors (Herin et al., 2005; Kehne et al., 1996), while 5-HT2C receptors 
have a large inhibitory role on locomotor activity (Fletcher, Sinyard, & Higgins, 2006; Steed 
et al., 2011). This activation of serotonergic receptors has been shown to exert its behavioural 
effect on locomotion by indirectly increasing DA release, particularly in mesolimbic pathway 
which projects to the nucleus accumbens (NAc) (Bubar et al., 2004; Callaway et al., 1991; 
Gold et al., 1989; McCreary et al., 1999). In support of this, the selective serotonin reuptake 
inhibitor fluoxetine has been shown to attenuate MDMA induced hyperactivity, with 
corresponding reduction in the efflux of DA in the striatum (Callaway et al., 1990; Gudelsky 
& Yamamoto, 2008). In addition, dopamine antagonists dose-dependently attenuated MDMA 
induced hyperactivity, indicating that activation DA receptors is integral to the locomotor 
stimulating effects of this drug (Bubar et al., 2004; Kehne et al., 1996). A rich interplay of 5-
HT and DA systems must therefore underlie the locomotor stimulatory effects of MDMA, 
whereby activation of both 5-HT and DA receptors are vital to this response. 
While both MDMA and amphetamine increase locomotor activity in the open field in 
rats, the spatial pattern of movement induced by each drug has been shown to differ (Martinez-
Price & Geyer, 2002). The type of locomotion induced by MDMA is characterised by a pattern 
of persistent forward locomotion predominantly around the perimeter of the chamber with 
avoidance of the centre, interrupted by occasional changes in direction (Figure 1.2) (Bankson 
& Cunningham, 2002; Callaway et al., 1991; Martinez-Price & Geyer, 2002; McCreary et al., 
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1999; Rempel et al., 1993), although increased central activity has also been observed 
(Kindlundh-Hogberg, Schioth, & Svenningsson, 2007; McCreary et al., 1999). Amphetamines, 
on the other hand, induce non-repetitive patterns of behaviour with frequent changing of 
direction that is distributed throughout all regions of the chamber including relatively long 
periods in the centre (Callaway et al., 1990; Geyer, Russo, Segal, & Kuczenski, 1987; Gold & 
Koob, 1989; Rempel et al., 1993). Therefore, while both MDMA and amphetamines may 
increase quantity of locomotor activity, the behavioural patterns produced by these two drugs 
seem to be characteristically distinct (Callaway et al., 1990). 
Decrease in central activity following MDMA exposure is likely related to 
augmentation of the serotonergic system, since this behaviour is not seen in amphetamine 
treated rats. In keeping with this, Rempel et al. (1993) found that a 5-HT1A/1B receptor agonist 
increased locomotor activity that was preferentially located in the periphery of the chamber 
similar to MDMA, supporting a role for 5-HT in the change in spatial pattern (Rempel et al., 
1993).  
 
Figure 1.2. The locomotor paths of rats injected with A. Saline, B. MDMA, C. amphetamine, or D. a 5-
HT1A/1B receptor agonist. Note that the locomotor activity after administration of MDMA or 5-
HT1A/1B agonist appears to be mostly confined to the periphery of the chamber. Adapted from 






Other behaviours that have been widely examined in open field tests with 
psychostimulant drugs are exploratory behaviours, such as rearing and nose holepokes. Rearing 
behaviour consists of animals standing on their hind legs in an upright posture and is considered 
to be a risk assessment behaviour, an orienting response, a means of scanning the environment, 
or a marker of environmental novelty (Ennaceur, 2014). Holepokes involve the animal poking 
its head into a hole in the floor of the testing apparatus, and is considered to be a measure of 
directed exploration, or neophilia (Brown & Nemes, 2008). A reduction in rearing behaviour 
or holepokes is generally thought to represent increased levels of anxiety, although it has also 
been considered to relate to general locomotor or exploratory activity (Thiel, Muller, Huston, 
& Schwarting, 1999). 
There is mixed evidence regarding the effect of MDMA on these exploratory 
behaviours in rats and mice (summarised in Table 1.1). Most studies have reported a significant 
reduction in rearing and holepoke activity in both rats and mice at doses greater than 3 mg/kg, 
while at lower doses there may be a paradoxical increase in rearing activity. Callaway et al. 
(1990) found in a study using male Sprague-Dawley rats that both rearings and holepokes were 
significantly reduced following doses of MDMA of 1.0 mg/kg or higher (Callaway et al., 
1990). In male CD rats, Kehne et al. (1996) determined that MDMA only suppressed rearing 
at doses of 20 mg/kg or higher, indicating that there may be strain dependent differences in 
sensitivity to MDMA (Kehne et al., 1996). In mice, reductions in rearing and holepoke activity 
have been consistently reported in doses greater than 3.3 mg/kg (Ferraz-de-Paula et al., 2011; 
Maldonado & Navarro, 2000; Scearce-Levie et al., 1999). Alternatively, other studies using 
Sprague-Dawley rats have found either no effect or an increase in rearing activity at doses of 
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3mg/kg (Bankson & Cunningham, 2002; Bubar et al., 2004; McCreary et al., 1999). Taken 
together these studies suggest that lower doses of MDMA may cause an increase in rearings 
while higher doses may suppress rearings. This paradoxical effect is supported by Palenicek et 
al. (2005) who found that 2.5 mg/kg increased, while 10mg/kg decreased, rearing activity in 
male Wistar rats. 
Contrary to these findings, Hernin et al. (2005) reported an increase in rearing activity 
using a similar paradigm in male Sprague-Dawley rats in doses up to 12 mg/kg, with a maximal 
effect seen at 8mg/kg, suggesting an inverse-U-shaped dose-response curve (Herin et al., 
2005). A possible explanation for this discrepancy in findings may relate to the methodology 
employed between studies; specifically, whether the rats were habituated to the testing chamber 
prior to testing. Introducing the animals to the testing arena prior to experimentation is expected 
to produce a reduction in exploration as the animal becomes familiar with the environment 
(Brown & Nemes, 2008; Hughes, 2007a). Therefore, habituation to the testing arena would 
serve to reduce rearing activity due to a lower neophilic exploratory drive. In the study by Herin 
et al. (2005) the experimenters habituated the rats for three hours per day for the three days 
prior to testing. The effect of habituation in this study is demonstrated by low amounts of 
rearing activity in the control animals, with less than 50 rearings on average for the 90 minute 
session. In contrast, Callaway et al. (1990) had no habituation sessions with their saline control 
rats performing approximately 130 rearings on average over a 60 minute session. This can be 
interpreted as a higher drive to explore the novel environment. On the other hand, habituation 
would be predicted to decrease stress-induced neophobia to a novel environment in MDMA 
exposed rats (Belzung & Griebel, 2001; Pare, Tejani-Butt, & Kluczynski, 2001). The fact that 
MDMA treated rats in the Callaway et al. (1990) study performed more rearings in the second 
30 minutes compared to the first 30 minutes may be related to reduced anxiety as these animals 
became habituated to the testing arena. Indeed, the behaviourally suppressive effects of other 
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hallucinogenic 5-HT2 agonists on investigatory behaviours have been shown to disappear in a 
familiar environment (Mittman & Geyer, 1989; Wing, Tapson, & Geyer, 1990). 
It seems, therefore, that the effect of habituation to the apparatus is to decrease rearing 
in saline control animals due to reduction in neophilia, while increasing the exploratory activity 
in MDMA treated rats due to reduction in neophobia. This hypothesis is supported by another 
experiment by Camarasa et al. (2008) who examined whether memantine (a nicotinic and 
NMDA receptor antagonist) would reverse memory impairments caused by acute MDMA 
administration in rats. In this experiment they habituated rats for six hours for the two days 
prior to testing, which they found almost eliminated rearing behaviour in the saline control rats, 
while MDMA treated rats (10 mg/kg) were found to have a significantly higher amount of 
rearing activity (Camarasa, Marimon, Rodrigo, Escubedo, & Pubill, 2008). Thus, habituation 
may, at least partly, explain the discrepancies between studies regarding the effect of MDMA 
on rearing activity. 
To conclude, MDMA may have an activating effect on exploratory behaviour at low 
doses, with an inhibitory effect at higher doses. Suppression of rearing activity may be a result 
of the anxiogenic effects of MDMA combined with the aversive effects of a novel environment. 
Alternatively, increased rearing activity in habituated rats may be due to reduced neophobia 
coupled with psychomotor stimulation. Future research addressing the effect of habituation on 





Table 1.1. Summary of animal studies examining the effects of MDMA on exploratory activity.  
Study Animals used Dose Behavioural test Outcome 
Callaway et al. (1990) 
Male Sprague-
Dawley rats 




Dose-depdendently reduced rearing and holepokes at 
doses at 1mg/kg or higher 
Scearce-Levie at al. (1999) Male 129/Sv mice 3.3, 10, 30mg/kg IP 
Rearings and 
holepokes All doses eliminated rearing and holepoke activity 
Kehne et al. (1996) Male CD rats 
1, 2, 3, 10, 20, 
40mg/kg IP Rearings 
Higher doses (20-40mg/kg) significantly reduced 
rearing, no effect for doses 10mg/kg or less 
Ferraz-De-Paula et al. 
(2011) Male BALB/c mice 
0.2, 1, 5, 8, 10, 
20mg/kg IP Rearings 
Reduced rearing activity with 5mg/kg or higher 
doses, no significant effect at low doses 
Maldonado & Navarro 
(2000) Male OF.1 mice 1, 8, 15mg/kg IP Rearings Significant reduction in rearing at 8 and 15mg/kg 
McCreary et al. (1999) 
Male Sprague-
Dawley rats 3mg/kg SC Rearings Inconsistent results 
O'Loinsigh et al. (2001) Male Wistar rats 20mg/kg IP Rearings Significant reduction in rearings 
Bankson & Cunningham 
(2002) 
Male Sprague-
Dawley rats 3mg/kg SC Rearings Inconsistent results 
Palenicek et al. (2005) 
Male and Female 
Wistar rats 
2.5mg/kg and 
10mg/kg SC Rearings 
2.5mg/kg increased rearing while 10mg/kg 
decreased rearing activity 
Bubar et al. (2004) 
Male Sprague-
Dawley rats 3mg/kg SC Rearings Significantly increased rearing 
Herin et al. (2005) 
Male Sprague-
Dawley rats 
2, 3, 4, 8, 12mg/kg 
SC Rearings 
Inverted-U-shaped response curve with maximal 




Anxiety is a negative emotional state associated with the perception of an ambiguous 
or potential threat (Ennaceur, 2014). Behavioural animal studies on MDMA and anxiety have 
produced mixed results and seem to demonstrate both anxiolytic and anxiogenic effects 
(Ferraz-de-Paula et al., 2011) (summarised in Table 1.2). Most studies have demonstrated an 
anxiogenic effect for MDMA in low to medium doses in a variety of behavioural tests. Doses 
of MDMA up to 10mg/kg have been shown to increase anxiety-like behaviours in the elevated 
plus maze (EPM) in mice and rats, with decreased total and open arm entries and markedly 
increased closed arm entries (Ho, Pawlak, Guo, & Schwarting, 2004; Lin, Burden, Christie, & 
Johnston, 1998; Morley & McGregor, 2000; Navarro & Maldonado, 2002). Morley & 
McGregor (2000) studied the effects of low doses of MDMA on male Wistar rats in a range of 
behavioural tests of anxiety including the EPM, a social interaction test, odour avoidance test, 
and footshock-induced ultrasonic vocalisations. They found that doses up to 5 mg/kg produced 
anxiogenic behaviour in most of these tests, with the exception of the social interaction test 
where there was a decrease in aggressive behaviour and increased duration of social interaction 
(Morley & McGregor, 2000). In the emergence test, emergence latency and increased hide time 
has been shown to be increased following low dose MDMA exposure in rats, again indicating 
an anxiogenic response (Jones, Brennan, Colussi-Mas, & Schenk, 2010; Morley, Arnold, & 
McGregor, 2005). 
Higher doses of MDMA have been reported to produce different results on anxiety 
depending on the test employed. MDMA at doses of 10 to 20 mg/kg have been reported by 
several studies as producing anxiolytic behaviour including increased time in the centre squares 
of the open field and increased entries and time spent in the open arms of the EPM, with some 
authors suggesting that MDMA may have anxiogenic effects at low doses and anxiolytic effects 
at high doses (Ferraz-de-Paula et al., 2011; Ho et al., 2004; Lin et al., 1998; Palenicek et al., 
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2005). However, in a predator odour test, Ferraz-de-Paula et al. (2011) found that 10 mg/kg 
MDMA increased the amount of time mice spent in the home chamber and decreased the 
number of risk assessments, suggesting increased levels of anxiety. The authors suggest that 
the apparent anxiolytic effect seen in the open field and EPM in these studies may have been 
due to MDMA altered locomotor activity rather than an effect on levels of anxiety per se. In 
support of this argument, Maldonado & Navarro (2001) found that 8 and 15 mg/kg MDMA 
resulted in a reduction in social investigation and an increase in avoidance and defence 
behaviours in a social interaction test in mice, which may represent anxiogenic behaviour. 
However, at these same doses there was no significant difference between MDMA and control 
rats in time spent in the light side of a light/dark box, although there was a significant reduction 
in transitions and rearing behaviour indicating a reduction in exploratory activity with no 
increased aversion to the bright light (Maldonado & Navarro, 2001). 
Taken together these results suggest that MDMA may have both anxiolytic and 
anxiogenic effects depending on the test situation, dose, and type of animal employed (Ferraz-
de-Paula et al., 2011; Morley & McGregor, 2000). MDMA tends to produce an anxiogenic 
response at low doses in most of these tests, while producing an anxiolytic effect in social 
interactions, suggesting that the prosocial effects may be mediated by different neural pathways 
than the effect on situational, or ‘state’, anxiety.
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Table 1.2. Summary of animal studies examining the effect of MDMA on anxiety 
Study Animals used Dose Behavioural test Outcome 
Lin et al. (1998) Male QS mice 1, 4, 12, 20mg/kg IP EPM 
4mg/kg decreased open arm entries and increased enclosed 
entries. 12mg/kg no effect on EPM. 20mg/kg increased time 
spent in the open arm. 
Morley & McGregor 
(2000) Male Wistar rats 1.25-5mg/kg IP 
EPM, social 




Increased anxiety-like behaviours in EPM at all doses. 
5mg/kg reduced time spent in proximity to cat odour stimulus 
and reduced footshock-induced ultrasonic vocalisations. 
Reduced aggressive behaviours and increased duration of 
social interaction. 
Maldonado & Navarro 
(2000) Male OF1 mice 1, 8, 15mg/kg IP LDB 
8 and 15mg/kg produced less transitions. No effect on time 
spent in light side of the box. 
Maldonado & Navarro 
(2001) Male OF1 mice 1, 8, 15mg/kg IP Social interaction 
8 and 15mg/kg produce decrease in aggression, reduced 
social investigation, and increase in avoidance and defence 
behaviours 
Navarro & Maldonado 
(2002) Male OF1 mice 1, 8, 15mg/kg IP EPM 
8mg/kg reduced time spent in open arms and increased 
number of entries in the closed arms. 15mg/kg had no effect 
on anxiety behaviours. 
Ho et al. (2004) Male Wistar rats 7.5 & 15mg/kg IP EPM 
7.5mg/kg increased latencies to enter open arms, less time in 
open arms, and more total arm entries, 15mg/kg produced 
increased open arm time. 
Palenicek et al. (2005) 
Male and Female 
Wistar rats 2.5 & 10mg/kg SC EPM 10mg/kg produced increased time in the open arms. 
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Morley et al. (2005) Male Wistar rats 5mg/kg IP 
Social interaction, 
LDB 
Increased social interaction including adjacent lying and 
approach behaviours. Increased hide time and emergence 
latency in emergence test. 
Jones et al. (2010) 
Male Sprague-
Dawley rats 1 & 3.3mg/kg IP Emergence latency 3.3mg/kg MDMA significantly increased emergence latency 
Ferraz-De-Paula et al. 
(2011) Male BALB/c mice 10mg/kg IP 
EPM, predator odour 
test 
In the EPM increased entries and time spent in the open 
arms.In a predator odour test increased time in the home 





Surprisingly few studies have been conducted looking at the acute effects of MDMA 
on memory and learning, with most studies focussing on the long-term sequelae of repeated 
MDMA administration (Kay et al., 2010). Numerous studies exist examining the chronic 
effects of MDMA on learning and memory, in both humans and animals. Some of these reports 
suggest that there is lasting neurocognitive deficit in recreational human users of MDMA, 
although this is inconclusive due to multiple confounders including poly drug use and comorbid 
mental health problems (Moratalla et al., 2015; Schenk, Harper, & Do, 2011). MDMA 
administration in animals has not produced a clear set of cognitive changes (Able, Gudelsky, 
Vorhees, & Williams, 2006). 
MDMA has been found to decrease accuracy and response rates in the delayed 
matching or non-matching to sample (DMTS or DNMTS) tasks in rats and pigeons after acute 
administration, indicating an impairment in working memory (Harper, Hunt, & Schenk, 2006; 
Harper, Wisnewski, Hunt, & Schenk, 2005; LeSage, Clark, & Poling, 1993; Marston, Reid, 
Lawrence, Olverman, & Butcher, 1999). Conversely, no significant impairment in this task was 
found in rhesus monkeys administered low-dose MDMA (up to 1 mg/kg) indicating that these 
deficits in working memory may only be apparent at higher doses (Frederick, Gillam, Allen, & 
Paule, 1995). However, it has been suggested that the overall impairment in the DMTS task 
may be due to an increased tendency to repeat the choice response made in the previous trial, 
known as proactive interference, rather than an impairment in working memory itself (Harper 
et al., 2006). This implies that rats either have trouble distinguishing between events that 
occurred in previous trials and the current one, or there is perseveration of responses indicating 
a lack of behavioural flexibility (Harper, 2013). In accordance with this, an increase in the time 
delay between trials was found to attenuate the MDMA induced impairment in this task, 
presumably by allowing rats to more easily discriminate current from previous-trial events, 
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indicating that working memory itself was not affected (Harper et al., 2006). Therefore, rats 
may remember episodic events within each trial, but they are impaired with respect to what 
they are supposed to do with the information they have, indicating impaired procedural, or 
reference, memory (Kay, 2010). Indeed, MDMA has been shown to preferentially disrupt 
reference memory processes in the eight-arm radial maze task in rats indicating that this drug 
impairs strategies for solving memory tasks which may, at least partly, explain apparent 
impairments in working memory seen in previous studies (Braida, Pozzi, Cavallini, & Sala, 
2002; Kay et al., 2010). 
From these studies it seems that MDMA may disrupt reference memory function while 
preserving working or short term memory. Alternatively, MDMA may disrupt both working 
and reference memory. More research on the acute effects of MDMA on memory are necessary 
using a variety of memory tasks in order to further clarify these memory deficits. The current 
paper will use a novel object recognition task, a test that has been shown to evaluate working 
memory, to this end. 
 
1.4.2 Acute behavioural effects of methylone. 
While there have been a number of studies looking at the pharmacology of methylone 
and new designer cathinones, relatively few studies have been conducted on the behavioural 
effects of methylone. Overall, the behavioural profile of methylone in animal studies has been 
shown to closely resemble that of MDMA (Gregg & Rawls, 2014). This is supported by the 
observation that methylone completely substitutes for MDMA in tests of stimulus 
generalisation in MDMA trained rats, with methylone (ED50=1.6 mg/kg) being about half as 
potent as MDMA (ED50=0.76 mg/kg) (Dal Cason, Young, & Glennon, 1997).  
29 
 
Consistent with the effects of psychostimulant drugs, several studies have found dose-
dependent increases in locomotor activity following injections of methylone (3 to 30 mg/kg) 
in both mice and rats (Gatch et al., 2013; Lopez-Arnau et al., 2013; Lopez-Arnau, Martinez-
Clemente, Pubill, Escubedo, & Camarasa, 2012; Marusich, Grant, Blough, & Wiley, 2012). In 
these studies the onset of action was rapid, with maximal stimulant effects between 0 and 30 
minutes post-administration, and lasted up to 4h post-administration. An ED50 of 1.48 mg/kg 
was calculated for male Swiss-Webster mice (Gatch et al., 2013). The increase in psychomotor 
activity was inhibited following haloperidol or ketanserin pre-treatment, suggesting 
involvement of DA and 5-HT systems, consistent with MDMA (Lopez-Arnau et al., 2012). 
There has also been shown to be a significant increase in rearing and forepaw treading 
following methylone administration in rats (Baumann et al., 2012). 
To date, no studies have directly compared the behavioural effects of methylone with 
MDMA in rats. While several studies have demonstrated increased locomotor effects after 
acute methylone administration, there appears to be no studies that have looked at the acute 
effects on memory and anxiety. 
 
1.5 Effect of Repeated Drug Exposure 
 
1.5.1 Effect of repeated exposure to MDMA. 
Human users of ecstasy have reported diminished subjective effects with repeated 
exposure, leading to increasing amounts of MDMA being consumed (Parrott, 2005). This has 
been attributed to the reduced 5-HT neurotransmission that temporarily occurs following 
repeated MDMA exposure, which may last for months after abstinence (Green, Mechan, 
Elliott, O'Shea, & Colado, 2003; Jones et al., 2010; Schenk & Bradbury, 2015). While there is 
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a widespread reduction in brain 5-HT following repeated high dose MDMA exposure, studies 
in rats have shown a simultaneous increase in DA neurotransmission in the NAc (Kalivas, 
Duffy, & White, 1998; Mayerhofer, Kovar, & Schmidt, 2001). Thus, repeated MDMA 
administration may lead to a behavioural tolerance to the serotonergic effects with concomitant 
sensitisation to dopaminergic effects (Schenk, 2011). Indeed both tolerance to, and 
sensitisation to, many of the behavioural effects of MDMA have been observed following 
chronic exposure (Jones et al., 2010). 
Human MDMA use also often involves repeated drug administration within a single 
session, known as ‘binge dosing’, in order to increase the subjective effects of the drug over a 
longer period of time (Docherty & Green, 2010). A number of studies have examined the effect 
of repeated exposure of MDMA using a variety of dosing paradigms. In rodents, a common 
research approach to model repeated exposure is to administer various doses of MDMA (5 to 
20 mg/kg) given one to four times per day over a short period of successive days (Harper, Kay, 
& Hunt, 2013). This strategy is thought to allow translation to human recreational use. For 
example, with 5 mg/kg administered three times at two hour intervals the peak plasma 
concentration in rodents is around 700 ng/mL, which closely resembles plasma concentrations 
during a high-dose binge of MDMA in recreational users (Rodsiri, Spicer, Green, Marsden, & 
Fone, 2011). 
Locomotor activity. 
Behavioural sensitisation or tolerance in locomotor activity may develop following 
MDMA exposure, which may depend on whether previous exposure is repeated intermittent 
dosing or a single high dose (Schenk & Bradbury, 2015). 
Several studies have demonstrated that multiple injections of MDMA of various doses 
for 3-5 days results in augmentation of locomotor activity to a further MDMA injection given 
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up to 4 weeks later when compared with controls. Sensitisation to the psychomotor stimulating 
effects of this drug is consistent with other abused psychostimulants (Ball, Wellman, 
Fortenberry, & Rebec, 2009; Bradbury, Gittings, & Schenk, 2012; Kalivas et al., 1998; 
McCreary et al., 1999; Spanos & Yamamoto, 1989). Repeated administration of MDMA 
enhances the capacity of the drug to elevate extracellular dopamine in the NAc, indicating that 
the sensitising effects of chronic exposure may be due to augmented DA neurotransmission 
(Kalivas et al., 1998). Consistent with this hypothesis, the sensitised locomotor response has 
been shown to be preferentially expressed in the centre of the box, resembling the locomotor 
activity that is produced by amphetamines (Bradbury et al., 2012; McCreary et al., 1999). This 
may also reflect tolerance to the anxiogenic properties of MDMA. 
Other studies have produced conflicting results. A study by Kindlundh-Hogberg et al. 
(2007) used three injections of 5 mg/kg (3 h apart) every week for four weeks in an attempt to 
model weekend-binge ecstasy use in humans. They found that although MDMA cause reduced 
SERT density in the NAc, there were no changes in the horizontal activity between weeks 
suggesting neither tolerance nor sensitisation (Kindlundh-Hogberg et al., 2007). Alternatively, 
Brennan and Schenk (2006) found that pre-treatment with a single high dose binge of MDMA 
(4 doses of 10 mg/kg 2h apart) resulted in behavioural tolerance to MDMA with reduced 
locomotor activity and a downward shift of the dose-response curve two weeks later. This 
effect was most likely due to impaired 5-HT neurotransmission as previously described. 
Tolerance was not apparent after twelve weeks, suggesting that the neuroadaptations to a single 
high dose binge of MDMA were reversible (Brennan & Schenk, 2006). 
Anxiety. 
It has been consistently demonstrated that repeated administration of MDMA can cause 
changes in anxiety-like behaviour in rats and mice for up to three months after exposure (Faria 
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et al., 2006; McGregor et al., 2003; Mechan et al., 2002; Morley, Gallate, Hunt, Mallet, & 
McGregor, 2001; Piper & Meyer, 2004). However, few studies have looked at whether there 
is tolerance or sensitisation following repeated exposure of MDMA on measures of anxiety. 
While the psychomotor activating effects of MDMA may become sensitised following 
repeated administration, there may be tolerance to the anxiogenic effects. Repeated 
administration has been shown to produce a shorter emergence latency from a dark box into an 
open field (Jones et al., 2010). Initial neophobia to open spaces observed with acute MDMA 
administration therefore seem to be attenuated after repeated exposure. The attenuated 
anxiogenic effect of MDMA following subchronic dosing is likely due to depletions of 5-HT, 
since repeated MDMA administration has been shown to prevent the anxiogenic effect of a 5-
HT2A receptor agonist in the elevated plus maze (Bull, Hutson, & Fone, 2004). Together it 
seems that there is acute tolerance to the anxiogenic effects of MDMA after repeated exposure. 
The current thesis will use the light/dark box to assess whether these findings can be replicated 
for MDMA and whether there is a similar behavioural tolerance for methylone. 
1.5.2 Effect of repeated exposure to methylone. 
Repeated administration of methylone in rats (3 or 10 mg/kg every 2 h for 3 doses) did 
not cause any reduction in cortical or striatal monoamine neurotransmitters two weeks after 
administration (Baumann et al., 2012). In contrast, at higher binging levels there has been 
shown to be a significant widespread depletion of 5-HT and 5-HT transporter levels in rats for 
up to two weeks post-administration (den Hollander et al., 2013; Lopez-Arnau, Martinez-
Clemente, Pubill, Escubedo, & Camarasa, 2014). This is consistent with the effects of repeated 
administration of MDMA.  
Repeated doses of methylone in mice followed by eight weeks of abstinence does not 
appear to affect locomotor activity, working or spatial memory in the T-maze, or anxiety as 
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measured by the elevated plus maze (den Hollander et al., 2013). Methylone treated rats did 
not demonstrate spatial learning deficits one week after binge exposure in the Morris Water 
Maze, although they displayed poorer performance in a single probe trial 24 h after the 
acquisition phase suggesting impaired reference memory (Lopez-Arnau et al., 2014). This is 
consistent with the finding that binge doses of methylone cause depletion of 5-HT in rats but 
not mice (den Hollander et al., 2013), and suggests a role for 5-HT in this memory task. 
No human or animal behavioural studies currently exist that have examined whether 
there is development of tolerance or sensitisation to the effects of methylone following repeated 
exposure. This will be examined in the current thesis. 
 
1.6 Adverse Effects and Hyperthermia 
 
1.6.1 Adverse drug effects of MDMA. 
Acute toxicity from MDMA ingestion relates to neuroendocrine, thermoregulatory, and 
cardiovascular systems. In a study of emergency department admissions due to the use of 
MDMA, the most severe complications were hyperthermia, hyponatraemia, rhabdomyolysis, 
cerebral oedema and coma, although the estimated ecstasy-related morbidity rate in recent 
users was very low (Halpern et al., 2011). It is important to note, however, that MDMA exhibits 
non-linear pharmacokinetics in human users, with a three-fold increase in dose of MDMA 
causing a six-fold increase in peak plasma concentration, suggesting that small increases in 
dose may lead to a disproportionate rise in plasma concentration, and thereby increasing the 
risk of acute toxicity (de la Torre, Farre, Ortuno, et al., 2000; de la Torre, Farre, Roset, et al., 
2000; Mas et al., 1999). 
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In rats, MDMA can produce signs of neural excitability with piloerection, 
hypersalivation, and urination, which are seen in oral doses above 25 mg/kg. At doses up to 
300 mg/kg there are tremors, convulsions, and death (Shulgin, 1986; Spanos & Yamamoto, 
1989). The LD50 is considerably lower for intraperitoneal administration, with the LD50 in 
Sprague-Dawley rats found to be 49 mg/kg (i.p.) (Hardman, Haavik, & Seevers, 1973).  
Hyperthermia. 
One of the most well recognised adverse event that can follow MDMA intoxication in 
recreational users is hyperthermia, with temperatures of up to 43oC being reported (Henry, 
Jeffreys, & Dawling, 1992). Hyperthermia is particularly concerning since this can precede 
DIC, rhabdomyolysis, and multi organ failure, with the majority of adverse reactions with core 
temperatures over 42oC being fatal (Cole & Sumnall, 2003b). 
In the rat, MDMA administration has generally been shown to cause a significant 
increase in core temperature of up to 2oC in a dose-dependent manner (Docherty & Green, 
2010; Green et al., 2003). This response has been shown in several studies to be dependent on 
ambient temperature. At normal or high ambient temperatures (> 20oC) MDMA causes a 
hyperthermic response, while at low ambient temperatures (< 17oC) MDMA has been shown 
to produce hypothermia (Green, O'Shea, Saadat, Elliott, & Colado, 2005). The hyperthermic 
effect was also found to be potentiated by social interaction (Kiyatkin, Kim, Wakabayashi, 
Baumann, & Shaham, 2014).  
Interestingly, in humans trials MDMA does not reliably cause an increase in core body 
temperature (Grob, Poland, Chang, & Ernst, 1996; Mas et al., 1999; Vollenweider et al., 1998), 
although significant mild increases in body temperature (< 1oC) have been recorded in some 
studies at higher doses of MDMA (Freedman, Johanson, & Tancer, 2005; Liechti et al., 2001; 
Parrott, 2012). It is likely that the hyperthermic response in human users is amplified in the 
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environments where MDMA is likely to be consumed, such as raves and night clubs where 
there is overcrowding, high ambient temperatures, and where they tend to consume little water 
together with considerable alcohol (Cole & Sumnall, 2003a; Green et al., 2003). 
The primary mechanism for MDMA induced hyperthermia in the rat appears to be 
impaired heat loss mechanisms due to sustained peripheral vasoconstriction, which prevents 
proper heat dissipation to the external environment (Kiyatkin et al., 2014). This would explain 
why changes in body temperature seen in rats after MDMA administration is so dependent on 
ambient temperature. However, the effect of MDMA on body temperature is complex due to 
the widespread actions of this drug on multiple neurotransmitter systems and their effects on 
both central thermoregulation and peripheral changes in blood flow (Docherty & Green, 2010). 
While cases of severe acute hyperthermia with MDMA are relatively unusual, the 
consequences can be fatal (Parrott, 2012). Since hyperthermia is related to significant toxicity, 
it is important to ascertain whether methylone also produces a similar temperature response 
which could have implications on its safety profile in human users. 
  
1.6.2 Adverse drug effects of methylone. 
Low recreational doses of synthetic cathinones enhance mood and increase energy, 
while high doses can cause serious medical complications. In humans, acute intoxication with 
methylone has been reported as causing seizure-like activity and hyperthermia leading to death, 
where peripheral blood concentrations were in excess of 0.5 mg/L (Pearson et al., 2012). In 
rats, methylone at high intraperitoneal doses (56 mg/kg) has been shown to cause tremors and 




Several studies have demonstrated a significant effect of methylone on body 
temperature in mice and rats (Baumann et al., 2012; den Hollander et al., 2013; Kiyatkin, Kim, 
Wakabayashi, Baumann, & Shaham, 2015). Multiple subcutaneous injections of methylone in 
rats (3 doses of 3 to 10 mg/kg 2 h apart) has been found to increase core temperature, but to a 
much lesser degree than that of MDMA (Baumann et al., 2012). Den Hollander et al., (2013) 
found that intraperitoneal doses of methylone at 30 mg/kg consistently produced a 2oC increase 
in body temperature in both mice and rats, as measured with a rectal probe (den Hollander et 
al., 2013). A recent study by Kiyatkin et al. (2015) looking at temperature changes in Long-
Evans rats administered with various doses of methylone (1 and 9mg/kg) found that methylone 
dose-dependently increased brain (NAc) temperatures by less than 2oC, which may be partly 
due to the peripheral vasoconstriction produced by the drug. This effect lasted for up to 4.5 
hours post administration. Unlike MDMA, there was no evidence of potentiation of this 
hyperthermic response by increased ambient temperature or during social interaction (Kiyatkin 
et al., 2015). 
 
1.7 Behavioural Tests Used in the Current Study 
 
In order to characterise the acute effects of MDMA and methylone, a wide battery of 
behavioural tests was used focussing on three domains: locomotor activity, anxiety, and 
memory. The tests used were selected based upon previous research on MDMA, as previously 
discussed. 
1.7.1 Open field test. 
The open field test is was originally developed by Hall (1934) to measure emotionality 
in rats. Since then it has become useful in observing a range of behaviours that relate to 
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psychomotor activity, anxiety, and exploration. In this test the animal is placed in an open 
Perspex box and allowed to move freely about the chamber for a designated amount of time. 
A variety of behaviours can then be observed and recorded. In the current study, recorded 
behaviours were horizontal locomotor activity (ambulation), the amount of time spent in the 
centre vs. periphery of the box, rearing behaviour, and number of faecal boluses. 
Abused psychostimulants such as cocaine and methamphetamine produce dose-
dependent increases in locomotor activity which reflects increased dopaminergic action in the 
NAc (Lopez-Arnau et al., 2012). Measurement of locomotor activity after administration of a 
drug is therefore an indirect measure of the activation of the reward pathways (Bubar et al., 
2004). Psychostimulants that produce greater locomotor hyperactivation may therefore have 
higher abuse potential. Conversely, any drug that fails to enhance locomotor activity may have 
a reduced chance of being an abused substance (Gatch et al., 2013). 
Avoidance of the central squares and suppression of rearing behaviour are useful 
indicators of anxiety. Avoidance of central squares and reduced rearing has previously been 
attributed to anxiogenesis (Jones et al., 2010; McCreary et al., 1999; Palenicek, Hlinak, 
Bubenikova-Valesova, Votava, & Horacek, 2007). 
 
1.7.2 Light/dark box. 
Tests of unconditioned anxiety in animal models is based on the conflict between the 
desire to explore novel environments and the tendency to avoid potentially dangerous 
environments, known as approach-avoidance behaviour (Kulesskaya & Voikar, 2014). The 
Light/Dark Box (LDB) test, developed by Crawley and Goodwin (Crawley & Goodwin, 1980), 
is a test for anxiety based on this approach-avoidance conflict which has been popular for 
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screening potential anxiolytic compounds (Kulesskaya & Voikar, 2014). During the test 
animals are placed in a dark box which has a door that leads into a brightly lit chamber. Animals 
are allowed to freely explore the protected (dark) and unprotected (bright) novel areas. This 
creates an approach-avoidance conflict between the animal’s innate aversion to brightly 
illuminated areas, and their exploratory drive towards novel environments. Several parameters 
are often measured to provide an anxiolytic profile of the drug, including the number of 
transitions between compartments and time spent in each compartment (Hascoet & Bourin, 
1998). 
 
The light/dark box has become a commonly used test for evaluating the anxiolytic 
properties of drugs in mice and rats, where differences in exploration can reasonably be 
attributed to the effect of the drug. Thus, an increase in exploration time in the brightly lit 
chamber or an increase in transitions between compartments is indicative of anxiolytic activity 
(Bourin & Hascoet, 2003). A third measure of anxiety in this test was the emergence latency 
time, or the time that it took for the rat to first move from the dark to the light area. Increased 
emergency latency is regarded as representing avoidance of a novel area, and therefore 
increased anxiety-like behaviour (Jones et al., 2010; Morley et al., 2005). 
 
1.7.3 Novel object recognition task. 
The novel object recognition (NOR) task (Ennaceur & Delacour, 1988b) measures non-
spatial memory in the rat, and is based on their spontaneous tendency to explore novel objects 
(Camarasa et al., 2008). In a standard NOR there is an acquisition trial which consists of 
exploration of two identical sample objects. After a delay, one of the objects is replaced with a 
novel object and exploration time of the novel object is measured, along with total exploration 
in both the acquisition and recognition phase. An increase in the relative time exploring the 
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novel object is seen as a measure of working memory. It has the advantage that it is quick and 
simple to perform, and has therefore been useful in assessing the short and long term effects of 
drugs of abuse on memory (Schenk et al., 2011). Since this task requires no previous reinforced 
training it is a more pure measure of working memory, with relatively little reference memory 
(Harper et al., 2013). 
 
1.8 Rationale and Hypotheses 
While there are a small number of studies that have examined the pharmacological 
aspects of methylone, few studies to date have examined the behavioural correlates of this 
potential substance of abuse. To our knowledge, no study exists that comprehensively 
compares the behaviour of methylone to MDMA, whose subjective effects methylone is said 
to closely resemble. In addition, no studies exist that look at the behavioural effects of 
methylone after repeated administration to determine if there is tolerance or sensitisation of the 
acute behavioural effects. 
Due to the ongoing high rates of abuse of MDMA and methylone, it is important to 
determine the acute and long-term effects of these drugs on health and neuropsychological 
functioning. Scheduling and controlling methylone may be warranted given its abuse potential, 
known psychostimulant effects, and implication in acute toxicity and death in recreational 
users. However, classification of this drug without pre-clinical behavioural data is problematic. 
Dose-response data are desirable for almost all new substances that are used either medically 
or recreationally by humans in order to determine "safe" and "hazardous" dosage levels. The 
first part of this research will therefore investigate the behavioural effects produced by different 
dosages of methylone in rats, and in particular, how similar they are to an equivalent dosage of 
MDMA on tests of locomotor activity, memory, and anxiety as outlined above. Since the 
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psychopharmacological response of methylone on extracellular monoamine levels is less than 
that of MDMA, and monoamine levels are considered to be responsible for the behavioural 
effects of amphetamine derivatives, it is hypothesised that methylone will have a dose-response 
characteristic that is approximately half that of MDMA. In addition, it is hypothesised that both 
MDMA and methylone will show significantly greater behavioural effects in female rats, 
consistent with previous research demonstrating greater locomotor effects in females for 
MDMA (Palenicek et al., 2005; Walker et al., 2007). Specifically it is hypothesised that both 
MDMA and methylone will cause enhanced locomotor activity confined to the periphery and 
reduced rearing activity. It is further hypothesised that MDMA and methylone will produce 
anxiogenic behaviours in the LDB and working memory impairments in the NOR task. 
Next this research will assess whether methylone produces behavioural tolerance or 
sensitisation similar to MDMA by injecting rats with a high binge dose of either MDMA or 
methylone and assessing their subsequent behaviour to a further challenge of the respective 
drug one week later. Behavioural sensitisation reflects many aspects of drug addiction, 
including the propensity of addicts to relapse (Ball et al., 2009). If the positive mood-altering 
effects of a drug are reduced following repeated exposure it may result in greater consumption 
of the drug per session, which can result in increased adverse effects of the drug, such as 
cognitive and psychiatric problems, and also increases the likelihood of overdosing with 
potentially harmful medical sequelae. Due to the similar psychopharmacological action and 
chemical structure between MDMA and methylone, it is hypothesised that methylone will 
produce a similar rapid behavioural sensitisation to the psychomotor activating effects and 
tolerance to the anxiogenic effects, as is observed from repeated exposure to MDMA. In 
addition, temperature measurements will be taken after acute intoxication, given that 




Finally, there are a limited number of studies that have looked at sex differences in the 
effects of MDMA. These studies have consistently shown that female rats are more sensitive 
to the locomotor stimulating effects of MDMA, consistent with the enhanced response of 
female rats to other psychostimulants, including cocaine and amphetamine (Palenicek et al., 
2005; Walker et al., 2007). This has important implications in terms of subjective and adverse 
effects of these drugs in female users, and may indicate an increased risk of physical or 
psychological harm. It is currently unknown whether similar sex differences occur following 
methylone intake. The current study will therefore use both male and female rats in order to 


















A total of 108 (54 male and 54 female) naïve adult PVG/C hooded rats (University of 
Canterbury, New Zealand) aged between 199 and 278 days old were used in the experiments. 
The use of 12 rats for each of the conditions was required in order to achieve more than 80% 
power. Both male and female rats were used since significant sex differences in the effects of 
acute MDMA administration in rats has been previously reported (Koenig et al., 2005; 
Palenicek et al., 2005). The weight of the animals ranged from 195 and 400g at the start of 
experimentation. The rats were housed in groups of 3-4 in large cages in a temperature 
controlled environment (21oC+/-1oC), with food and water ad lib. A 12h light/dark cycle was 
in operation and all testing took place during the light cycle. Experimentation was approved by 




Methylone ((±) 2-methylamino-1-[3,4-methylenedioxyphenyl]propan-1-one) and 
MDMA ((±) 3, 4-methylenedioxymethamphetamine hydrochloride) were obtained from BDG 
Synthesis (Wellington, NZ) and were shown to have greater than 99% purity by HPLC. 
Methylone and MDMA solutions were prepared at various concentrations (2.5mg/mL, 
5mg/mL, 8mg/mL, and 12mg/mL) by dissolving 25mg, 50mg, 80mg, or 120mg of powder in 
10mL of normal saline (0.9% NaCl w/v), respectively. Normal saline alone was used as the 
control solution. These solutions were then transferred to air-tight injection vials, and were 





2.3.1 Procedure for the acute behavioural effects of MDMA and methylone. 
  The 108 rats were randomly assigned to one of 9 experimental conditions; MDMA 
2.5mg/kg, MDMA 5mg/kg, MDMA 8mg/kg, MDMA 12mg/kg, Methylone 2.5mg/kg, 
Methylone 5mg/kg, Methylone 8mg/kg, Methylone 12mg/kg, or vehicle (saline 0.9%), with 12 
rats per condition (6M and 6F). 
  2.3.1.1 Drug Administration. 
On experimental days, groups of 9 rats (either 1 M or 1 F for each condition) were 
weighed and then returned to their home cage. Drug doses were calculated for each rat (at 
1mL/kg), and appropriate volumes of each of the drug solutions were drawn into 1mL i.p. 
injection syringes and were labelled. Twenty minutes prior to testing, individual animals were 
removed from their home cage, injected intra-peritoneally in the right lower quadrant of the 
abdomen with the appropriate syringe, and were then returned to their home cage. All 
experiments were done in standardised laboratory conditions, under a normal light/dark cycle, 
at an ambient temperature of 21±1oC and an average light level of approximately 360 lux. 
2.3.1.2 Behavioural Testing. 
  On the first day of testing, rats received the appropriate dose of drug and were 
subsequently tested in both the open field test and light/dark box test (2.3.1.1. and 2.3.1.2). One 
week later rats were injected again with the same dose of drug and were tested in the object 
recognition task (2.3.1.3). Half of the rats were counterbalanced and were tested in the object 
recognition test on the first day of testing and open field test and light/dark box test one week 
later. The observer scoring the behaviour was blinded to condition. 
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Open Field Test. 
Twenty minutes post-injection each animal was placed in a novel open field (610 x 610 
x 250 mm) with clear Perspex sides and a black plastic floor which was divided into 16 square 
blocks (each 152mm x 152mm) which was outlined on the field floor in white paint. Each block 
corresponded to a spatial location designated by an (x,y) parameter, which ranged from (1,1) 
for the bottom left corner to (4,4) for the top right corner (Figure 2.1). The rat was placed in 
the centre of the open field facing away from the observer, and a timer was started. Open field 
activity was recorded by an observer every 3 seconds for 5 minutes on a scoring sheet by noting 
down the spatial location of the rat (the square in which the greatest proportion of the rat’s 
body was at the time of the recording), and whether the rat was displaying any rearing activity 
at that time. If the rat did not change location a dash (-) was noted. 
 
(1,4) (2,4) (3,4) (4,4) 
(1,3) (2,3) (3,3) (4,3) 
(1,2) (2,2) (3,2) (4,2) 
(1,1) (2,1) (3,1) (4,1) 
        FRONT  
Figure 2.1. Aerial view of base of the open field with spatial location parameters. The lighter shaded 




Following testing the rat was returned to its cage and the testing arena was cleaned by 
spraying the floor and sides with Powerquat Blue (2%) and wiping down with a paper towel. 
This was to remove any olfactory cues left in the box between trials. 
Path length was calculated by adding up the total number of blocks entered during the 
5 minute trial and multiplying this by 15.2cm (length of one box) to give a total displacement 
(in cm). The total number of blocks entered was determined by calculating the x and y change 
between each 3 second interval, and summing these changes for all intervals. 
Time spent in the centre was calculated for each rat by totalling the number of times 
that the rat was noted to be in the centre of the apparatus (lighter shaded region - figure 2.1) 
during the 5 minute trial, and multiplying this total by 3. 
Rearing activity was calculated as the total number of times that the rat stood on its 
hind legs in an upright posture during the 5 minute trial. 
 
Light/Dark Box Test. 
The apparatus consisted of a clear varnished wooden box comprising two 300mm long 
x 200mm wide x 300 mm high compartments. The compartments were separated by a wooden 
partition with a 100mm x 100mm doorway that could be closed by means of a guillotine slide.  
One compartment was covered by a hinged wooden lid (dark side), and the other was covered 
by a hinged clear Perspex lid (light side). A camera was situated 50cm above the top of the box 





Immediately following the open field test (approximately 25 minutes post-injection) 
the rat was placed into the dark side of the light-dark box and, 10 seconds later, the guillotine 
slide was removed. The observer sat 2 m from the apparatus facing the TV screen so that they 
were obstructed from view of the rat. By means of a hand-held counter and timer, the observer 
recorded the emergence latency from the dark side (time until all 4 paws of the rat are placed 
into the light side), the number of transitions between the two sides, and the total time spent in 
the light side.  At the end of the 5-min trial, the rat was returned to its home cage, and both 
sides of the box were cleaned by spraying the floor and sides with Powerquat Blue (2%) and 
wiping down with a paper towel. 
 
Object Recognition Test. 
Testing took place in a square wooden arena (600 x 600 x 250 mm) which had black 
painted walls and floor. A miniature video camera was situated above the arena which was 
projected onto a 13” TV screen. The TV was viewed by the observer so that they were 
obstructed from view of the rat. Behaviour was observed and analysed in real time by the 
observer. The duration of exploration of each of the objects was measured by stopwatch, where 
exploration was defined as directing the nose at a distance of less than 2 cm to the object and/or 
touching it with the nose (Ennaceur & Delacour, 1988a). 
 
One week after the open field test and light/dark box testing, rats were habituated to the testing 
arena for 2 minutes, after which they were removed, injected with the appropriate dosage of 
drug, as outlined above, and returned to their home cage. Twenty minutes post-injection, rats 
were exposed to two identical objects in the arena for a 5 minute acquisition period, and then 
returned to their home cage. After a 15 minute inter-trial delay, rats were placed back in the 
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arena for a 3 minute trial, with the original objects being replaced with one identical and one 
novel object. The objects used were a green plastic cup (which was half-filled with sand to 
prevent the rats from knocking it over) and a large black plastic lid with a hollow centre. The 
two sets of objects were used during each test session and the objects used as the “original’ and 
“novel” objects were counterbalanced within and across groups to avoid potential object-
preference bias. 
 
2.3.2 Procedure for repeated drug exposure. 
One week following behavioural testing (section 2.3) the drug naïve rats and rats from 
the lowest dose (2.5 mg/kg) drug groups were used to assess the level of biological tolerance 
of methylone and MDMA. Animals were used from the lowest dose group of prior drug 
administration to ensure that any carry-over effect from previous exposure was minimal. 
2.3.2.1 Drug Administration. 
    Both MDMA and Methylone were dissolved in normal saline (0.9% NaCl w/v) at a 
concentration of 5.0 mg/mL and were injected intraperitoneally (i.p) at a volume of 1 mL/kg. 
Rats from the MDMA group were administered with 5.0 mg/kg of MDMA every hour for 3 h 
on each of 2 consecutive days to give a total cumulative dose of 30 mg/kg. Rats from the 
methylone group received the same dosing regimen using methylone 5.0 mg/kg. Control rats 
received equivalent injections of 0.9% saline. 
 
2.3.2.2 Body temperature. 
       Body temperature of the rats was recorded every hour immediately following each 
administration of the drug, and 1 hour after the last injection. Body temperature was measured 
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using a Braun ThermoScan ExacTemp Thermometer (IRT 4020). During recording the probe 
of the thermometer was placed into the external auditory meatus and held until reading of the 
tympanic membrane temperature was completed (approx 3 s). Temperature was recorded twice 
in each ear and the readings were averaged. This tympanic temperature reading technique has 
been shown to provide an accurate and rapid measure of core temperature in rats that is highly 
correlated with rectal temperature (Morley et al., 2001). 
 
2.3.2.3 Behavioural Testing. 
       One week following drug administration, and 20 minutes prior to behavioural testing, 
rats received a 5 mg/kg challenge injection of MDMA, methylone, or equivalent volume of 
0.9% saline, and were returned to their home cage. Twenty minutes post-injection, rats were 
tested in the open field and light/dark box as outlined previously, with counterbalancing 
between the two tests. Following testing all rats were returned to their home cage. 
 
2.4 Statistical Analysis 
 
Data was analysed using Statistica 10 software package for windows. T-tests for 
independent means were carried out between drugs for each behavioural test to determine if 
there were overall significant differences in the effects of each drug. Factorial ANOVAs were 
calculated for each drug for each of the behavioural tests. When significant main or 
interaction effects were found, post-hoc comparisons were made using one-tailed Dunnett’s 
tests to compare all doses with saline control, and Tukey’s HSD to establish pair-wise 





3.1 Acute Behavioural Effects of MDMA and Methylone 
3.1.1 Open field test. 
Descriptive statistics for displacement, time in centre, and number of rearings were 
calculated by drug type for all rats. T-tests for independent means were calculated between the 
means of the MDMA and methylone groups for each measure (Table 3.1). 
One of the male rats in the 12mg/kg group died following injection, and was therefore 
unable to be used to complete the open field test. The data used for analysis contained data 
from 12 rats per group (6M and 6F), with only 11 rats in the 12mg/kg MDMA group (5M and 
6F). 
There was a significant difference between the MDMA and methylone groups on the 
measure of time spent in centre, with MDMA rats spending significantly more time in the 
centre than methylone rats. There was also a significant difference in the number of rearings 
with MDMA rats having significantly less rearing behaviour than methylone rats. There was 
no significant difference in the mean displacement between MDMA and methylone while 
collapsing across dose. 
Two-way factorial ANOVAs were used to calculate effects of each drug (MDMA and 
methylone) for each of the behavioural tests in the Open Field, with dose and sex as the 
independent factors. Assumptions of normality and homogeneity of variance were assumed to 
be satisfied given that the methodology was appropriate for the investigations, and there was 
independence between observations. In addition, the two-way ANOVA is known to be robust 
against violations in normality and homogeneity of variance when sample sizes are equal 
within groups, as there was in the current experiment. Therefore small violations of these 
assumptions are not likely to interfere with results. (reference?) 
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Table 3.1. Means and Standard Deviations of Open Field Responses with T-tests Between the Means of all MDMA and all Methylone Groups 






Descriptive statistics for displacement can be found in table 3.1. Factorial two-way 
ANOVAs were calculated for each drug (MDMA and methylone), with displacement as the 
dependent variable and dose and sex as the independent factors. There was a significant main 
effect of dose for MDMA (F(4, 49) = 5.04, p = .002) and methylone (F(4, 50) = 17.44,  p < 
.001), with increasing doses of each drug producing a greater displacement (fig. 3.1), consistent 
with the hypotheses. Post-hoc comparisons using Dunnett’s test showed that all doses of 
MDMA and methylone produced significantly greater displacement than saline vehicle. 
Tukey’s test showed no significant differences between doses for MDMA, but demonstrated 
that 12mg/kg methylone had significantly greater displacement than low doses (2.5 and 
5mg/kg), indicating that higher doses of methylone continued to increase displacement above 
lower doses, while MDMA reached its maximal effect on displacement at 2.5mg/kg. A 
significant main effect was found for sex for both MDMA (F(1, 49) = 4.80, p = .033) and 
methylone (F(1, 50) = 7.32, p = .009), with females having a significantly higher level of 
displacement in both groups (Figure 3.1). This is consistent with previous research 
demonstrating a greater effect of MDMA on psychomotor stimulation in female rats, and 
suggests that methylone also has a significantly greater stimulant effect on females. There were 
no significant sex X dose interactions for either drug group. While the difference between drug 
groups overall did not reach significance (Table 3.1), a t-test for independent means between 
the high dose groups (8 and 12mg/kg) of each drug showed a significant difference (t(45) =      
-2.39, p = .021), with methylone causing higher levels of displacement than MDMA. This 
indicates that the maximal effect of methylone on psychomotor stimulation was greater than 








Figure 3.1. Mean displacement (cm) in the open field for MDMA and methylone treated rats by dose of 
drug administered (mg/kg). A. Mean (± SEM) displacement for rats injected with either MDMA, 
methylone, or saline vehicle. * p<.05 methylone compared with saline; # p<.05 MDMA compared with 
saline B. Mean (± SEM) displacement for male and female rats administered MDMA. C. Mean (± SEM) 






Time in centre. 
The spatial characteristics during each trial were determined by measuring the amount 
of time the rat spent in the centre four squares of the open field. A summary of the descriptive 
statistics for time spent in the centre can be found in Table 3.1. Factorial two-way ANOVAs, 
with time spent in the centre as the dependent variable and sex and dose as independent factors, 
were calculated for each drug. A significant main effect of dose was found for MDMA (F(4, 
49) = 2.59, p = .048), with increasing doses of MDMA causing an increase in the time spent in 
the centre (Figure 3.2), contrary to the original hypothesis. Post-hoc contrasts with Dunnett’s 
test showed that only high doses (8 and 12mg/kg) were significantly different from saline 
control, indicating that MDMA-induced changes in spatial characteristics of locomotion were 
only produced at higher doses.  There was no main effect for methylone (F(4, 50) = 0.63, p = 
0.646) suggesting that there was no effect of this drug on the spatial characteristics of 
movement about the chamber. There were no significant main effects of sex for either drug, 
and there were no significant sex X dose interactions. 
 
Figure 3.2. Mean time spent in the centre of the open field (s) for MDMA and methylone treated rats 




Descriptive statistics for number of rearings can be found in Table 3.1. Factorial two-
way ANOVAs, with rearings as the dependent variable and sex and dose as the independent 
factors, were calculated for each drug. There was a significant main effect of dose for both 
MDMA (F(4, 49) = 44.36, p < .001) and methylone (F(4, 50) = 9.02, p < .001), with each drug 
causing a significant decrease in rearing (Figure 3.3), consistent with the hypothesis. In 
addition, a t-test for independent means between MDMA and methylone showed that MDMA 
significantly reduced rearing activity more than methylone (Table 3.1). Post-hoc comparisons 
with Dunnett’s test showed that all doses of MDMA significantly reduced rearing relative to 
saline control, but for methylone only doses of 5mg/kg or higher significantly reduced rearing. 
There was no significant main effect of sex or sex X dose interaction for either drug. 
 
 
Figure 3.3. Mean number of rearings in the open field for MDMA and methylone treated rats by dose 
administered (mg/kg). * p < .05 compared to saline. Error bars denote ± SEM. 
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3.1.2 Light/Dark box. 
Descriptive statistics for amount of time spent in the light (time in light), number of 
transitions between light and dark sides, and emergence latency (how long it took for the rat to 
first emerge from the dark side after the start of the trial) were calculated by drug type and can 
be found in Table 3.2. One of the male 12mg/kg rats died prior to testing, and was therefore 
excluded from analysis. Five rats failed to emerge from the dark box (1 from MDMA 8mg/kg, 
2 from MDMA 12mg/kg, and 2 from Methylone 5mg/kg groups) and were also excluded from 
analysis. T-tests for independent means were conducted between the MDMA and methylone 
group means for each of the parameters, all of which were not significant (Table 3.2). Two-
way factorial ANOVAs were used to analyse the light/dark box results for each drug, with time 
in the light side of the box, number of transitions between compartments, and emergency 









Table 3.2. Means and Standard Deviations of Light/Dark Box parameters with T-tests Between the Means of all MDMA and all Methylone Groups 





Time in light. 
While it appeared from the graph of mean time in the light vs. dose for each drug that 
there was a trend towards an increase in time spent in the light with increasing dose (Figure 
3.4), there was no main effect of dose for either MDMA (F(4, 46) = 1.27, p = 0.30) or 
methylone (F(4, 48) = 1.02, p = 0.41). There was a significant main effect of sex for MDMA 
(F(1, 46) = 8.31, p = .006) with males spending more time in the light, on average, than females. 
There was no main effect of sex for methylone (F(1, 48) = 3.13, p = 0.083), and there were no 
significant sex X dose interactions for either drug. The current data suggest that although 
female rats spend more time in the light side of the box on average, there is no significant effect 
of either drug on total time spent in the light compartment. 
 
 
Figure 3.4. Mean time spent in the light compartment of the LDB (s) for MDMA and methylone treated 
rats by dose administered (mg/kg). Error bars denote ± SEM. 
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Transitions between light and dark compartments. 
There was a significant main effect of dose for both MDMA (F(4, 46) = 2.97, p = .029) 
and methylone (F(4, 48) = 4.35, p = .004), with higher doses resulting in a greater number of 
transitions between the light and dark compartments (Figure 3.5). Post-hoc comparisons with 
Dunnett’s test showed that there were only significant differences from saline control at 8 and 
12mg/kg of MDMA, and 12mg/kg of methylone. This indicates that high doses of either drug 
cause a significant increase in transitions. There were no significant main effects of sex for 
either drug, and no significant sex X dose interaction effects.  
 
 
Figure 3.5. Mean number of transitions between the light and dark compartments of the LDB for MDMA 
and methylone treated rats by dose administered (mg/kg). * p < .05 MDMA compared to saline. # p < 
.05 methylone compared to saline. Error bars denote ± SEM. 
 
Emergence Latency. 
There was no main effect of dose on emergency latency in the ANOVA for either 
MDMA (F(4, 51) = 1.27, p = 0.293) or methylone (F(4, 53) = 1.14, p = 0.349), although the 
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graph of the mean emergence latency vs. dose indicated a trend towards increased latency with 
increasing doses of MDMA and methylone (Figure 3.6). Failure to reject the null hypothesis 
was likely due to the large standard errors for this parameter at higher doses. There was also 
no significant main effect of sex for either drug, and no significant sex X dose interaction 
effects. The current data therefore fails to demonstrate a significant difference in the emergence 
latency between drug-treated animals and saline controls. 
 
 
Figure 3.6. Mean emergence latency from the dark side of the LDB (s) for MDMA and methylone treated 
rats by dose administered (mg/kg). Error bars denote ± SEM. 
 
3.1.3 Novel object recognition task. 
During the object recognition task, the amount of time that the rat spent in exploring 
each of the novel (a) and identical (b) objects was recorded. Descriptive statistics for the mean 
exploration time for each drug are summarised in Table 3.3. Because one of the male 12mg/kg 




Table 3.3. Means and Standard Deviations of Novel Object Recognition Task parameters with T-tests Between the Means of all MDMA and all 





MDMA rats failed to explore in this task and was therefore excluded. Novel and identical object 
times were used to calculate total exploration time (e = a + b), and a discrimination index (d1 
= a / (a + b)) where d1 > 0.5 indicates higher discrimination between novel and identical objects, 
as previously described (Schenk et al., 2011). In addition, the side on which the novel object 
was placed (Left or Right) and the object chosen to be the novel item (Lid or Cup), were 
recorded, and t-tests were used to determine if there was place or object preference. Two-way 
ANOVAs were calculated for each drug, with total exploration time and discrimination as the 
dependent variables and sex and dose as the independent factors. 
 
Object and place preference. 
A t-test for independent means showed that there was a significant difference in mean 
novel exploration time between the lid (M = 14.60, SD = 10.88) and cup (M = 21.74, SD = 
11.87), with the cup having a higher amount of novel exploration time (t(210) = 3.273, p = 
0.001), indicating a preference for that object. There was no significant difference between 
means in total exploration time for side, indicating that there was no place preference. 
 
Exploration time. 
There was no main effect of dose on exploration time for either MDMA or methylone 
(Figure 3.7), indicating that these drugs did not impair exploratory activity, although there 
appeared to be a trend towards less total exploration time for MDMA treated rats at higher 
doses. There was a significant main effect of sex for both MDMA (F(1, 48) = 4.93, p = .032) 
and methylone (F(1, 50) = 7.74, p = .008), with females having a higher amount of total 




Figure 3.7. Mean total exploration time (s) of objects in the novel object recognition task (NOR) for 




Figure 3.8. Mean total exploration time (s) of objects in the novel object recognition task (NOR) by 




A single sample t-test showed that the discrimination between the novel and identical 
objects was significantly greater than 0.5 (t(105) = 7.10, p < .001), indicating that the rats were 
able to discriminate to a level greater than chance, on average. From the two-way ANOVAs 
there were no significant main effects of dose for either MDMA (F(4, 48) = 0.45, p = 0.776) 
or methylone (F(4, 50) = 0.28, p = 0.888) (Figure 3.9), indicating that there was no difference 
in object discrimination for rats exposed to either drug. There was also no main effect of sex 
for either drug. Since exploration time was also not affected by either drug, these results fail to 
demonstrate an impairment in working memory from acute methylone or MDMA exposure in 
this task. 
 
Figure 3.9. Mean discrimination index (d1) in the object recognition task for MDMA and methylone 





3.2 Temperature Change with Repeated Drug Administration 
Temperature was recorded for 9 rats out of each drug group (4M and 5F) immediately 
at the time of the first injection (0 hours) and then at the time of each additional injection, and 
finally one hour after the last (third) injection, making a total of 4 measurements per rat. Means 
and standard deviations can be seen in Table 3.4. 
 
Table 3.4. Means and Standard Deviations of Temperatures of Rats During and After Repeated 




A repeated measures ANOVA, with temperature recordings as the repeated measure, 
time as the within group factor, and treatment (saline, MDMA, or methylone) as the between 
groups factor, showed a significant between-subject effect of treatment (F(2, 23) = 8.22, p = 
.002), a significant within-subject effect of time (F(3, 69) = 5.97, p = 0.001), and a significant 
Time X Treatment interaction (F(6, 69) = 6.96, p < .001). Linear contrast analysis showed that 
there was a significant increase in temperature for MDMA rats (F(1, 23) = 123.24, p < 0.001), 
but no significant change in temperature for methylone (F(1, 23) = 3.82, p = 0.062) or control 
rats (F(1, 23) = 2.81, p = 0.106) over time. The increase in temperature was not evident until 1 
hour following the first dose of MDMA, and peaked 1 hour following the final dose (Figure 
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3.10). Further temperature recordings may have shown an even greater increase in temperature 




Figure 3.10. Mean temperature of rats (oC) during repeated administration of 5mg/kg of MDMA, 
methylone, or equivalent volume of saline vehicle over time (h). Black arrows denote injection times. 
* p < .05 compared with saline. Error bars denote ± SEM. 
 
3.3 Unexpected Deaths and LD50 
Four of the 12 binge dosed (BD) MDMA rats (all males) died several hours after the 
first 15mg/kg binge dosing. They were therefore unable to be used in the following behavioural 
testing procedures and were excluded from statistical analysis. 
The LD50 for male PVG/c hooded rats appears to be much lower than the LD50 for male 
Sprague-Dawley rats, which has previously been reported to be 49mg/kg (i.p.) (Hardman et al., 
1973), given that 4 of 12 male rats died after 15mg/kg, and 2 of 24 male rats died after 12mg/kg 
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(i.p.). Based on this data, using probit maximum likelihood estimation, an LD50 was calculated 
for male PVG/c hooded rats. The iterations returned an estimated 0.5 probability of 16.14mg 
(CI[14.42, 28.87], p < .05), indicating that the LD50 of MDMA for male rats was much lower 
than previously reported.  
 
3.4 Behavioural Testing Following Repeated Drug Exposure 
Two-way factorial ANOVAs were used to compare the 5mg/kg MDMA and methylone 
rats and saline controls from section 3.1 (Drug Naïve, DN, group) to rats who had been given 
a 5mg/kg challenge of their respective drug (or saline vehicle for control rats) one week after 
the binge dosing regimen (Drug Treated, DT, group). Because 4 of the male MDMA rats died 
during binge-dosing they were not able to complete testing and were excluded from analysis. 
 
3.4.1 Open field test. 
The dependent measures in the Open Field Test were displacement, time in centre, and 
rearings, with drug type (saline, MDMA, Methylone), sex (M and F), and exposure (DN and 
DT) as the independent factors. 
Locomotor Activity. 
There were significant main effects for sex and drug type consistent with the results 
from section 3.1. However, there were no significant differences between DN and DT rats in 
measures of displacement (Table 3.5). Further, there were no significant drug X exposure 
interactions for any of the drug groups. The current results indicate that there was no evidence 
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for sensitisation or tolerance to either drug on the measure of locomotor activity following 
binge dosing. 
Time in centre. 
There was a significant main effect of drug type, however there were no significant 
main effects of sex or exposure (Table 3.5). There were no significant drug X exposure 
interactions for any of the drug groups. The results indicate that there was no significant effect 
of binge dosing of either drug on the amount of time rats spent in the centre of the open field. 
Rearings. 
There was a significant main effect of drug, but again there were no significant main 
effects of sex or exposure (Table 3.5). However, there was a significant sex X exposure 
interaction with both MDMA (F(1, 56) = 4.840, p = 0.032) and methylone (F(1, 56) = 6.614, 
p = 0.013) DT female rats demonstrating a greater number of rearings compared to DN rats, 
indicating a tolerance to the suppressive effect on rearing for both of these drugs. There was 
no significant difference in rearings for saline treated female controls (F(1,56) = 0.423, p = 
0.518), indicating that this effect was not due to habituation or repeated testing. There was no 








Table 3.5. F-ratios of Open Field Tests for DN and DT rats: Exposure (Between DN and DT 
Rats, Collapsed Across Drug Type and Sex), Drug Type (Between MDMA, Methylone, and 
Saline Collapsed Across Exposure and Sex), and Sex (Between M and F Rats, Collapsed Across 
Exposure and Drug Type). 
 
3.4.2. Light/Dark box. 
Dependent measures for the light/dark box were the same as in section 3.1. The 
independent factors were sex, drug type, and exposure (DN and DT). 
Time in the Light. 
A two-way ANOVA showed a significant main effect for exposure (F(1, 54) = 4.19, p 
= 0.045). Post-hoc contrast analysis revealed that MDMA and methylone DT rats spent less 
time in the light side of the box than MDMA and methylone DN rats, on average (t(40) = 2.61, 
p = .013) (Figure 3.11). Saline controls showed no significant difference in time spent in the 
light between DN and DT groups, indicating that there was no effect of repeated testing or 
habituation. There was no main effect of drug type (F(2, 54) = 1.73, p = 0.187), however 
contrast analysis showed a significant difference between MDMA and methylone DT rats and 
saline controls (t(32) = 2.40, p = 0.022), with drug-treated rats showing significantly less time 
in the light. There was no main effect of sex (F(1, 54) = 1.68, p = 0.206). The data suggests 
      
Open Field Tests 
Exposure Drug Type Sex 
F(1,56) P F(2,56) P F(1,56) p 
Displacement 0.858 0.358 28.18 0.000* 19.19 0.000* 
Time in Centre 1.426 0.237 8.12 0.001* 0.449 0.505 
Rearings 3.027 0.087 29.12 0.000* 0.598 0.442 
  * significant to p < 0.01       
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that following repeated drug exposure both MDMA and methylone rats had significantly 
reduced time in the light side of the LDB. 
 
Figure 3.11. Mean amount of time spent in the light side of the LDB for MDMA, methylone and saline 
treated rats by exposure to drug. DN = Drug Naïve, DT = Drug Treated. * p < .05 compared to 
control. Error bars denote ± SEM. 
 
Number of Transitions. 
There was a significant main effect of exposure (F(1, 54) = 5.68, p < .001 ), with DT 
rats displaying fewer transitions between the light and dark sides of the box than DN rats 
(Figure 3.12). Again, post-hoc contrast analysis showed that this decrease was significant for 
MDMA and methylone groups (t(40) = 2.76, p < 0.01),  with no significant difference between 
saline controls. There was no overall main effect of drug type (F(2, 54) = 1.38, p = 0.26). 
Contrast analysis showed a significant difference between drug-treated and control DN rats 
(t(32) = 2.16, p = .038), with drug-treated rats having a significantly higher number of 
transitions than controls, consistent with findings in section 3.1.2. However, following drug 
exposure there was no significant difference in number of transitions between drug-treated and 
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saline control rats. There was no main effect of sex (F(1, 54) = 1.11, p = 0.296). These results 
indicate that repeated exposure to MDMA and methylone attenuates the increase in transitions 
that was seen earlier after acute drug administration. 
 
 
Figure 3.12. Mean number of transitions between the light and dark compartments of the LDB for 
MDMA, methylone, and saline treated rats by exposure to drug. DN = Drug Naïve. DT = Drug 
Treated. * p < .05 compared with control. Error bars denote ± SEM. 
 
Emergence Latency. 
There were no significant main effects of exposure, sex, or drug type, suggesting that there was 
no effect of repeated exposure of either drug on emergence latency. In addition, there were no 








4.1 General Summary 
The current study aimed to investigate the acute behavioural effects of methylone and 
compare these effects to MDMA, a drug which has been extensively studied previously and 
has shown to be chemically and psychopharmacologically similar to methylone. Given the 
similarities in action on monoamine neurotransmitters, it was expected that methylone would 
resemble MDMA in its behavioural profile. However, because methylone has previously been 
shown to augment monoamine neurotransmission to a lesser degree than MDMA, it was 
expected that methylone would produce a behavioural response that is approximately one-half 
of that of MDMA. 
The results demonstrated that MDMA and methylone do produce similar patterns of 
behaviour in many aspects, however the two drugs were not identical. In the open field, both 
drugs increased psychomotor activity as evidenced by enhanced horizontal locomotion, 
although methylone produced a greater response than MDMA, contrary to our hypothesis. This 
enhancement of activity was stronger in females for both MDMA and methylone treated rats, 
suggesting that females are more responsive to the pscyhostimulating properties of these drugs. 
MDMA, but not methylone, produced increased activity counts in the centre of the open field, 
which was surprising given several previous reports that MDMA enhanced locomotor activity 
in the periphery of the open field (Martinez-Price & Geyer, 2002; Rempel et al., 1993). Anxiety 
related behaviours were inconsistent, with MDMA and methylone reducing rearing, but having 
no effect on light avoidance or emergence latency and increasing the number of transitions 
between compartments in the LDB. In the object recognition task there was no significant effect 
on exploration time or object discrimination by either drug, indicating that MDMA and 




The second aim of the current study was to determine the effect of a repeated binge-
like exposure on the subsequent development of behavioural tolerance or sensitivity on these 
tests. There was no effect of previous exposure to MDMA or methylone on locomotor activity 
or time in the centre of the open field. For female rats, there was a significant difference in 
rearing activity before and after repeated drug exposure, indicating a disinhibition of the 
suppressing effect of MDMA and methylone on this behaviour. In the LDB there was a 
reduction in time spent in the light side of the compartment and reduced transitions following 
repeated exposure to either drug, indicating that there was more anxiogenic behaviour. 
Finally, MDMA but not methylone significantly increased body temperature of male 
and female rats during repeated binge administration, with several fatalities in male rats. Deaths 
were unexpected as the dosing strategy used was similar to those used in previous studies. 
These findings highlight some important similarities and differences in the acute and 
subacute behavioural effects of MDMA and methylone exposure. The following is a discussion 
of these findings, with limitations of the current study, their implications for humans, and 
suggestions for possible future research. 
 
4.2 The Acute Behavioural Effects of MDMA and Methylone 
MDMA and methylone are psychostimulant drugs which act on monoamine 
neurotransmitter by enhancing the release and blocking the reuptake of 5-HT, DA and NA 
(Cozzi et al., 1999). As expected, the behavioural correlates of acute MDMA and methylone 
exposure were similar, but not identical, and were in many aspects consistent with previous 




4.2.1 Locomotor activity. 
Both MDMA and methylone enhanced horizontal locomotor activity. This finding was 
consistent with previous research and supported the hypothesis of the current research 
(Callaway et al., 1991; Callaway et al., 1990). Also consistent with the hypotheses was the 
observation that female rats were more sensitive to the stimulant effects of these drugs. 
However, there were two findings which were unexpected; that methylone rats had 
significantly greater displacement than MDMA treated rats at higher doses, and that MDMA 
rats failed to display peripheral localisation of activity as seen in previous studies. 
Displacement. 
It was hypothesised that MDMA would have a greater effect on horizontal locomotor 
activity than methylone. While no studies have directly compared the behavioural effects of 
these two drugs previously, this hypothesis was supported by previous findings that MDMA 
has a greater effect on monoamine neurotransmission than methylone (Nagai et al., 2007; 
Sogawa et al., 2011), and that augmentation of monoamines has been shown to underlie the 
acute behavioural effects of psychostimulant drugs (Gudelsky & Yamamoto, 2008). 
Specifically, the ability of a drug to increase locomotor activity correlates with its ability to 
release DA in the mesoaccumbens pathway (Bubar et al., 2004). In the current study methylone 
was found to have a greater maximal effect on horizontal locomotor activity than MDMA, 
indicating that this drug causes a greater efflux of DA in this pathway.  
Although methylone continued to increase ambulation as the dose increased, the 
hyperactivity induced by MDMA reached a maximal effect after a relatively low dose (2.5 
mg/kg). This is contradictory to previous findings in other strains of rat which have 
demonstrated dose-dependent increases of locomotor activity up to 20 mg/kg (Kehne et al., 
1996; Spanos & Yamamoto, 1989). The discordance between studies may be explained by 
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competing behaviours at higher doses of MDMA such as anxiety, stereotypies, or serotonin 
syndrome behaviours such as low body posture, all of which have previously been associated 
with reduced ambulation (Herin et al., 2005; Scearce-Levie et al., 1999). Indeed, higher doses 
of amphetamine-like stimulants have been shown to result in a phase of focused stereotypy 
during which locomotion declines, and this has been demonstrated in MDMA-sensitised 
Sprague-Dawley rats even at low doses (Ball, Klein, Plocinski, & Slack, 2011). This was the 
first study to use PVG/c rats, and it is possible that these rats may be more sensitive to the acute 
effects of MDMA, evidenced by lethality in some rats at 12 mg/kg. Thus, it is possible that at 
higher doses rats were developing other non-ambulatory behaviours with consequential 
interruption of horizontal activity. 
Another possible explanation relates to the relative potencies of MDMA and methylone 
on various monoamine systems. The neurochemical actions of methylone have been shown to 
resemble MDMA, but with a reduced efficacy at increasing extracellular 5-HT levels relative 
to DA (Baumann et al., 2012; Cozzi et al., 1999). Previous studies have shown that 5-HT 
release can antagonise the stimulant and reinforcing properties of DA release seen with 
administration of psychostimulant drugs (Rothman & Baumann, 2006). Therefore, the higher 
relative effect of MDMA on 5-HT release may dampen the dopaminergic psychostimulant 
effects, while in methylone the reduced capacity to release 5-HT would have the opposite 
effect. This has important implications for the addictive potential of these drugs. 
Activation of 5-HT1B receptors seems to be the critical initiating event in the 
psychomotor activation caused by MDMA. A selective 5-HT1B receptor antagonist failed to 
attenuate the locomotor activity caused by methylone, suggesting that this receptor does not 
play a role in methylone induced hyperlocomotion (Lopez-Arnau et al., 2012). Methylone may 
therefore be closer to amphetamines in its locomotor effects. In agreement with this, methylone 
has been found to be a direct agonist of 5-HT2A receptors, which are known to be targets of 
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amphetamine compounds that mediate locomotor responses, and which may be partially 
responsible for its effects on locomotor activity (Lopez-Arnau et al., 2012). 
Consistent with previous research, the stimulatory effects of MDMA were more 
pronounced in female rats (Palenicek et al., 2005; Walker et al., 2007). This was the first study 
to demonstrate a similar disproportionate increase in the locomotor enhancing effect in female 
rats for methylone. This finding is important as it implies that the acute stimulant effects of 
both MDMA and methylone could be higher in female human users, which could increase the 
risk of unwanted effects and adverse clinical outcomes. The importance of including both male 
and female animals in pre-clinical research is highlighted by this finding. 
 
Central square occupancy. 
MDMA has consistently been shown to increase locomotor activity in the periphery of 
the open field with avoidance of the centre in rats at doses up to 10 mg/kg (Palenicek 2005, 
Bankson and Cunningham 2002, MCreary 1999, Callaway 1990). In the current study MDMA 
administration dose-dependently increased time spent in the centre of the chamber, contrasting 
with the findings of these earlier studies.  
In the open field test, anxiogenic drugs have been reported to increase time spent in the 
peripheral zone while decreasing exploration of the centre (Fraser et al., 2010), and it therefore 
could be concluded that centre avoidance seen after MDMA treatment may due to 
anxiogenesis. However, evidence suggests that the confinement to the periphery of the chamber 
after acute MDMA exposure may be due to the onset of thigmotaxis, rather than a consequence 
of increased anxiety. This is supported by the finding that familiarisation with the testing 
environment fails to change the pattern of locomotor activity, indicating that increased anxiety 
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is unlikely to be responsible (Callaway et al., 1991). In agreement with this, Palenicek et al. 
(2005) found that 10 mg/kg MDMA produced locomotor stimulation confined to the periphery 
of the chamber in Wistar rats, however these same rats displayed anxiolytic behaviour in the 
EPM, also suggesting that the confinement to the periphery was not due to anxiety (Palenicek 
et al., 2005). 
It is unclear why the doses of MDMA used in the current study resulted in increased 
central activity. One explanation may be related to unrecorded observations of the MDMA 
treated rats which demonstrated significant focussed stereotypy of ambulation between the 
corner and centre in a small circular pattern, particularly in higher doses. This pattern of circular 
ambulation differs from that observed previously and may be due to an unusually higher 
sensitivity of the PVG/c rats to the stereotypic effects of MDMA. A shift from goal-directed to 
purposeless stereotypic locomotion has been previously demonstrated with higher doses of 
dopaminergic psychostimulants, and has been attributed to activity at the D2 autoreceptor 
(Koulchitsky et al., 2016). It is possible that at higher doses MDMA may preferentially activate 
D2 receptors, resulting in a change of motor activity from peripheral localisation to focussed 
stereotypies within the chamber. This theory is supported by a study by Kindlundh-Hogberg et 
al. (2007), who demonstrated that acute administration of high dose MDMA (3 doses 5 mg/kg 
doses) to male Sprague-Dawley rats significantly increased activity in the centre of an open 
field (Kindlundh-Hogberg et al., 2007). Therefore, MDMA may produce qualitatively different 
ambulation patterns depending on the dose or strain of animal used. Furthermore this change 
in activity may be independent of anxiety levels and is more likely due to the psychomotor 
stimulating and stereotypic behaviours produced by this drug. 
There was no significant effect of methylone on the spatial characteristics of locomotor 
activity, suggesting that this drug does not produce the same characteristic patterns of 
stereotypic behaviour seen in MDMA. Since methylone seems to produce psychomotor 
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stimulation independent of 5-HT1B receptors, the current findings support the notion that it is 
the activation of serotonergic receptors that is responsible for the spatial patterns of locomotor 
activity induced by MDMA (Rempel et al., 1993). Further studies using higher doses of 
MDMA in other breeds of rat may help to determine if the increase in central activity is a 
function of dose, strain, or a combination of both. Psychopharmacological studies may then 
prove useful to find the neurochemical basis of this behaviour.  
 
4.2.2 Rearing activity. 
It was hypothesised from previous research that MDMA would suppress rearing 
activity. The results confirm this hypothesis, with a dose-dependent reduction in rearing 
activity for all doses. It was also demonstrated that methylone significantly reduced rearing 
activity in a similar fashion, although the effect of MDMA on this behaviour was greater than 
methylone. 
The suppression of exploratory activity may be due to a combination of factors 
including anxiety, serotonin syndrome behaviours, or decrease in exploratory drive. Firstly, it 
has previously been demonstrated that forced exploration in a novel environment causes 
elevations in “state” anxiety; that is, anxiety that is experienced in a particular moment in time 
and is enhanced by the presence of an anxiogenic stimulus (Belzung & Griebel, 2001; Hughes, 
2007a). It has also been demonstrated that MDMA administration causes increased anxiety-
like behaviour in a number of paradigms (Ferraz-de-Paula et al., 2011). Therefore the 
combination of MDMA and novel environment may cause high levels of anxiety in these 
animals, leading to a reduction in exploratory behaviour. Alternatively, it has been proposed 
that the reduction in rearing may be due to the onset of serotonin syndrome, characterised by 
low body posture, splayed hind legs, and floor sniffing, which would interfere with vertical 
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activity levels (Bubar et al., 2004; Palenicek et al., 2005; Spanos & Yamamoto, 1989). Indeed, 
in the current study rats seemed to demonstrate many of these behaviours (unrecorded 
observations). It is also possible that the onset of stereotypies may interrupt normal exploratory 
behaviour. Indeed, both a reduction in rearing activity and high levels of stereotypy were 
concurrently recorded after 20 mg/kg i.p. in male Wistar rats (O'Loinsigh, Boland, Kelly, & 
O'Boyle, 2001). Therefore, the reduction in rearing seen in the animals in the current study may 
be due to a combination of increased anxiety, stereotypies, and serotonin syndrome behaviours. 
Close examination of these behaviours in psychostimulant treated rats may help to further 
elucidate this distinction. 
The neural mechanisms involved in MDMA-induced changes in rearing activity are not 
currently known, but studies have shown that it involves both serotonergic and dopaminergic 
mechanisms. Rempel et al. (1993) found that administration of a 5-HT1B/1A receptor agonist 
significantly decreased investigatory behaviour including rearing, and at higher doses virtually 
eliminated this behaviour. However, Scearce-Levie et al. (1999), found that 5-HT1B knockout 
mice had suppression of rearing behaviour following MDMA administration similar to wild-
type controls, suggesting that reductions in exploratory behaviour following administration of 
MDMA occurs via a mechanism other than activation of the 5-HT1B receptor. In contrast, 5-
HT1A and 5-HT2 agonists have been shown to reduce exploratory behaviours, while 5-HT2B/2C 
antagonists significantly potentiate MDMA induced rearing activity (Bankson & Cunningham, 
2002; Mittman & Geyer, 1989; Wing et al., 1990). Bubar et al. (2004) found that MDMA 
(3mg/kg) consistently and robustly enhanced vertical rearing activity, and that this response 
was blocked by administration of D1 or D2 antagonists, suggesting that both D1 and D2 receptor 
activity are necessary to maintain normal rearing behaviour, as well as enhancing vertical 
rearing behaviour after MDMA administration. This finding indicates that normal DA activity 
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is necessary for exploratory behaviour, and that disruption of the dopaminergic pathways is the 
basis for the suppression of these activities.  
It has been previously demonstrated that 5-HT2C receptor mediated neurotransmission 
is associated with anxiogenic effects (Bagdy, Graf, Anheuer, Modos, & Kantor, 2001; Vicente 
& Zangrossi, 2014). The 5-HT2C receptor is also known to be localised to regions containing 
DA cell bodies and has an inhibitory role in the control of mesolimbic DA efflux (Bankson & 
Cunningham, 2002). Therefore, this receptor may be responsible for the reduction in rearing 
activity by suppressing dopaminergic pathways in response to the neophobia towards the novel 
environment. Alternatively, activation of other 5-HT receptors, such as 5-HT1A, may cause 
disruption of the DA system by activation of D2 autoreceptors, which is known to induce 
stereotypic behaviour, and which could disrupt normal goal directed behaviour (Koulchitsky 
et al., 2016). Further studies targeting 5-HT receptor subpopulations is necessary to further 
characterise the neural basis of this behaviour. 
Methylone was found to dose-dependently decrease rearing activity. This was 
consistent with the effects of MDMA, but contrary to the findings of Baumann et al. (2012) 
who found an increase in rearing activity after repeated administration of methylone (3 doses 
of 3 or 10mg/kg administered 2 h apart). However, in this study the behavioural observations 
were done while the rat was in its home cage, which could have removed the neophobic 
response that would be expected under observation in a novel environment. Therefore, 
methylone can cause a reduction in exploratory activity in a novel environment that may not 
be seen in a familiar environment. This provides evidence that methylone shares 
psychopharmacological effects with MDMA in this response, since both drugs produce 




Taken together, these results suggest that both MDMA and methylone can cause 
suppression of rearing activity which may be due to activation of 5-HT2C or 5-HT1A receptors 
with subsequent disruption of normal dopaminergic activity. Since methylone produced similar 
results to MDMA in its effects on rearing activity, it may be inferred that the action of 
methylone on rearing activity is via neural mechanisms that are qualitatively similar to MDMA. 
 
4.2.3 Light/dark box and anxiety. 
The light/dark box provides a measure of unconditioned anxiety (Hascoet & Bourin, 
1998). It was hypothesised that MDMA and methylone would produce anxiety-like behaviours 
in this test. The results showed that there was no significant difference in time that rats spent 
in the light side of the box, suggesting that there was no aversion to the bright light in this task, 
and at higher doses of both drugs it seemed that there was a trend towards increased time spent 
in the bright chamber. There was a significant increase in the number of transitions for both 
drugs, with higher doses resulting in an increased number of transitions. Finally, although there 
was a trend towards increased emergence latency with increasing doses of MDMA and 
methylone, this did not reach statistical significance. 
The current study found that MDMA did not significantly affect time spent in the light 
side of the box, which was consistent with previous research (Maldonado & Navarro, 2000). 
Methylone also failed to produce any significant changes in this parameter. It has previously 
been suggested that an increased time in the bright chamber is associated with decreased 
aversion and this seems to be the most reliable parameter to assess anxiolytic activity of drugs, 
since this provides the most consistent dose-effect results (Hascoet & Bourin, 1998; Young & 
Johnson, 1991). However, the LDB test is known to produce false positive results on this 
parameter if the drug increases general locomotor activity (Bourin & Hascoet, 2003). In the 
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current study, both MDMA and methylone produced robust increases in locomotor activity. 
Therefore, the finding that drug treated animals did not significantly differ in the amount of 
time spent in the light side of the box may reflect the psychomotor stimulating properties of 
the drugs rather than the anxiety levels of the animals. 
The number of transitions was initially thought to be an index of anxiety, however 
studies have not consistently shown changes to this parameter with anxiolytic drugs. This has 
lead researchers to believe that this parameter may be more dependent on sedative or 
psychostimulant properties of drugs, with decreased transitions a result of sedation (Bourin & 
Hascoet, 2003; Hascoet & Bourin, 1998). Transitions may be therefore be an index of activity-
exploration. In the current study there was an increase in the number of transitions for both 
MDMA and methylone rats. This is consistent with the hypothesis that the number of 
transitions reflects general psychomotor activity, and like time spent in the light side of the 
chamber, may not be a useful measure of anxiety in psychostimulant drugs. 
There was no significant change in emergence latency for either drug, which is contrary 
to previous findings of an increased emergence latency for MDMA (Jones et al., 2010; Morley 
et al., 2005), although there was a general trend towards increased emergence latency with 
increasing doses of either drug. In addition, five of the rats (3 MDMA and 2 methylone) failed 
to emerge from the dark chamber which may be a function of high anxiety levels. As with the 
other LDB parameters, emergence latency may have been influenced by the psychomotor 
stimulant properties of the drugs, and may therefore not be a reliable measure of anxiety levels 
in rats for these drugs. 
An anxiolytic effect has been consistently reported in the EPM after moderate-high 
doses of MDMA, with increased entries and time spent in the open arms, which has lead 
researchers to suggest that MDMA may cause anxiogenesis in low doses and anxiolysis in high 
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doses (Lin et al., 1998). This contrasts with research using high dose MDMA in mice in the 
predator odour and social interaction tests which have suggested anxiogenesis at high doses 
(Ferraz-de-Paula et al., 2011; Maldonado & Navarro, 2001). In the LDB test, the current study 
found no evidence of changes in anxiety levels. There was a significant increase number of 
transitions, however as stated previously, this was likely to be secondary to the psychomotor 
stimulating or stereotypic effects of these drugs resulting in purposeless or non-goal directed 
ambulation throughout all areas of the testing arena (Koulchitsky et al., 2016). For this reason 
the EPM and LDB may be insensitive tests for the anxiogenic or anxiolytic effects of 
psychostimulants in animals, and previous findings of apparent anxiolytic behaviour in these 
tests may have also been confounded by psychomotor stimulation or stereotypies. Further 
studies using a wider range of tests that are not influenced by psychomotor activity may help 
to further understand the effects of MDMA and methylone on anxiety. 
The neurochemical basis of anxiety seen after acute MDMA administration is poorly 
understood, with most research focussing on serotonergic mechanisms. In particular, there are 
a number of studies that suggest that the 5-HT2C receptor is important in the expression of 
MDMA-induced anxiety. Hallucinogenic 5-HT2 agonists have been shown to produce 
increased neophobic reactions to a novel environment which is attenuated by familiarisation 
(Mittman & Geyer, 1989). In addition, a selective 5-HT2C receptor antagonist was shown to 
cause significant anxiolysis in a bright unfamiliar arena compared to saline controls, and 
reversed the anxiogenic effects of the SSRI antidepressants fluoxetine and sertraline in a social 
interaction test (Bagdy et al., 2001; Wing et al., 1990). It has also been shown that a 5-HT2C 
receptor antagonist reduces the suppressive effect of MDMA on rearing behaviour (Bankson 
& Cunningham, 2002). More recently, Jones et al. (2010) found that the increased emergence 
latency caused by MDMA treatment in Sprague-Dawley rats was dose-dependently attenuated 
by a selective 5-HT2C receptor antagonist. Therefore the 5HT2C receptor may be important for 
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the expression of fear towards novel or aversive stimuli in MDMA and methylone treated rats. 
Other serotonin receptors have also been implicated in the anxiogenic effects of MDMA with 
less consistent results (Morley et al., 2005). However, with at least 14 different 5-HT receptor 
subtypes, the effect of MDMA on anxiety is likely the consequence of activation of multiple 
receptor subtypes in different brain regions (Lin & Parsons, 2002). More research is necessary 
to further classify the effects of these receptor subtypes. 
It is important to remember that the topic of anxiety is complex, and the effects of 
MDMA and methylone on this behaviour is likely to involve multiple brain regions and 
neurotransmitter systems (de la Mora, Gallegos-Cari, Arizmendi-Garcia, Marcellino, & Fuxe, 
2010). Previous research has demonstrated that MDMA tends to produce an anxiogenic 
response in most behavioural tests at low doses, while producing an anxiolytic effect in social 
interactions, suggesting that the pro-social effects may be mediated by different neural 
pathways than the effect on state anxiety (Morley et al., 2005). There are environmental factors, 
sex, species, and strain differences that are likely to cause differences in drug effects on anxiety 
(Bourin & Hascoet, 2003; Clement, Le Guisquet, Venault, Chapouthier, & Belzung, 2009). 
Finally, various models of anxiety are not equivalent. Models based on spontaneous responses 
to aversive or novel environments may produce different types of anxiety to those based on 
conditioning (Belzung & Griebel, 2001). All of these factors are important to consider when 
investigating the effects of drugs on anxiety behaviours. In the current experiment there was 
almost identical behaviours exhibited between MDMA and methylone treated rats suggesting 
similar neuropsychological effects, although the LDB may be in some ways insensitive to the 






Previous research has demonstrated that acute MDMA exposure may impair reference 
memory with sparing of working memory (Harper et al., 2006; Harper et al., 2005). 
Alternatively it may affect both working and reference memory (Braida et al., 2002). The 
current study used the NOR task, which is thought to be a relatively pure measure of working 
memory with relatively little reference memory (Harper et al., 2013). The NOR task in the 
current study demonstrated that rats were able to discriminate between a novel and identical 
object, since there was a mean discrimination ratio significantly greater than chance. There was 
no significant difference in object discrimination between vehicle and drug-treated rats for 
either MDMA or methylone. In addition, there was no significant difference in total exploration 
time between drug and saline treated rats, indicating that neither drug impaired exploratory 
drive. These results extend on previous findings and provide further evidence that MDMA does 
not acutely impair working memory. Furthermore, this is the first study investigating the effects 
of methylone on memory, and demonstrates that acute methylone treatment also does not 
significantly impair working memory. 
While the neuropharmacology of memory deficits caused by acute MDMA 
administration remain largely unknown, the deficit in reference memory seems to be related to 
the serotonergic action of MDMA. Van Wel (2011) found that the 5-HT2A/2C receptor blocker 
ketanserin prevented MDMA induced impairment in the word learning task in human subjects, 
suggesting that MDMA induced impairments in verbal working memory are in large the result 
of direct or indirect stimulation of the 5-HT2A/2C receptors. However, ketanserin failed to 
prevent impairment of spatial or prospective memory. Using field potential recordings in rat 
hippocampal slices, Rozas et al. (2011) demonstrated that acute application of MDMA 
enhanced long term potentiation (LTP) in CA1 hippocampal neurons which involved 
presynaptic 5-HT2A/2C serotonin receptors and postsynaptic D1/D5 dopamine receptors, 
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indicating that MDMA impairs memory through a polysynaptic interaction between 
serotonergic and dopaminergic systems in the hippocampus. Administration of MDMA causes 
activation of 5-HT2A/2C on dopaminergic terminals, causing the release of DA which acts on 
D1/D5 receptors in the postsynaptic CA1 neurons in the hippocampus. Alterations in D1 firing 
in this area causes disruptive effects on memory. The involvement of D1 receptors was also 
implicated in findings by Harper (2013) who found that a D1 receptor antagonist was able to 
attenuate the disruption caused by MDMA on a delayed matching to sample task in rats 
(Harper, 2013). 
The current findings suggest that acute MDMA and methylone intoxication may not 
significantly impair working memory in human users, and gives weight to the suggestion that 
memory deficits seen in studies on humans may be secondary to non-mnemonic processes, 
such as attention. Future research should aim to test working and reference memory in humans 
while simultaneously testing for other cognitive and emotional processes and psychomotor 
coordination that may interfere with the testing procedure itself. In addition, the current study 
only addressed acute administration of these substances. Chronic self-administration of 
MDMA by rats has been shown to impair performance on this task when tested one week 
following the last administration of drug, indicating that chronic exposure may, at least 
temporarily, disrupt working memory (Schenk et al., 2011). Acute and chronic MDMA 
exposure may therefore disrupt different memory processes. Further research examining 






4.3 Repeated Drug Exposure 
The second part of the current thesis examined whether there was behavioural tolerance 
or sensitisation to the acute effects of MDMA or methylone after binge-type dosing. Previous 
research has produced mixed results with some showing sensitisation and some tolerance to 
the behavioural effect of this drug. The current study will build on these previous findings and 
is the first to determine if there is any behavioural tolerance or sensitisation following repeated 
exposure to methylone. Rats were dosed with 5mg/kg MDMA or methylone every hour for 
three hours on each of two consecutive days. One week later behaviour was tested in the open 
field and light/dark box following a further 5 mg/kg challenge of their respective drugs. 
4.3.1 Open field test. 
It was hypothesised that there would be behavioural sensitisation to the locomotor 
stimulating properties of MDMA and methylone following binge dosing. The results 
demonstrated no difference in locomotor activity for either MDMA or methylone. This is 
surprising given the number of previous studies that have demonstrated behavioural 
sensitisation following subacute dosing (Ball, Budreau, & Rebec, 2006; Ball et al., 2011; Ball 
et al., 2009; Bradbury et al., 2012; Kalivas et al., 1998). The differences in findings may be 
related to the differences in dosing regimens, the withdrawal period, or the context of exposure. 
The development of tolerance or sensitisation has been shown to be dependent on 
whether the dose is repeated intermittent dosing or a single high dose binge (Schenk & 
Bradbury, 2015). Studies that have demonstrated sensitisation have generally used daily or 
twice daily dosing for three to five days. The current experiment used binge doses on two 
consecutive days which may have been an insufficient number of days to produce sensitisation. 
A second possibility relates to the withdrawal period. Kalivas et al. (1998) demonstrated that 
the sensitising effect of pre-exposure was evident in high dose binge rats after a withdrawal 
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period of twelve days, although after 48 hours there was no sensitisation, concluding that the 
sensitisation is delayed (Kalivas et al., 1998). Indeed most studies demonstrating sensitisation 
have done so after a delay of twelve days or longer. Therefore the use of a one week withdrawal 
period in the current study may not have been long enough to allow the neurocognitive changes 
necessary for augmentation of the effects of MDMA to occur. In contrast, a study by Ball et al. 
(2006) found sensitisation in locomotor activity after a three to five day withdrawal period, but 
only in rats who received their sensitising doses in the apparatus used for behavioural testing 
rather than in the home cage. This finding of “dependence on context of exposure” has been 
consistently replicated, and suggests that the consequential development of sensitisation to 
MDMA is dependent on the context in which the drug is given, particularly following short 
withdrawal periods (Ball et al., 2011; Ball et al., 2009). In the current study the drug was given 
in the home cage which could have reduced the effect of sensitisation. Future research on 
tolerance and sensitisation to the effects of psychostimulants should be aware of these 
procedural manipulations and the effect they could have on behavioural outcomes. 
The underlying mechanisms of the augmented locomotor response to MDMA are not 
clearly known, and may be due to repeated effects on DA neurotransmission or via altered 5-
HT receptor mechanisms (Schenk & Bradbury, 2015). McGregor et al. (2003) found that a two 
day binge of MDMA could alter 5-HT receptor density 3 months after exposure, with high dose 
exposure causing an increase in 5-HT1B receptor density in the NAc, but low dose causing a 
decrease in 5-HT1B density in other brain regions. Given the importance of these receptors in 
the locomotor response to MDMA, this differential response could at least partly account for 
why different dosing regimens can lead to different outcomes. Alternatively, the increased 
sensitivity to MDMA after repeated administration may be a consequence of structural changes 
to the DA system through neuroplasticity (Schenk, 2011). Ball et al. (2009) found that 
intermittent binge dosing of MDMA for three weeks can cause reorganisation of synaptic 
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connectivity in the limbic-cortico-striatal circuitry, with increases in dendritic spine density in 
the NAc. More recently, Lettfuss et al. (2013) have proposed that behavioural sensitisation may 
be mediated by muscarinic receptors (Lettfuss, Seeger-Armbruster, & von Ameln-Mayerhofer, 
2013). More research is necessary to determine what underlying changes occur from repeated 
MDMA and methylone exposure, and what experimental manipulations may enhance or reduce 
this effect. 
Unfortunately the current experiment failed to replicate earlier findings of behavioural 
sensitisation in locomotor activity following acute MDMA exposure. This may have been due 
to the strain of rat used or due to the experimental procedures used as previously mentioned. It 
remains unknown whether methylone is capable of producing behavioural sensitisation or 
tolerance after repeated administration. Further research on this topic is recommended. 
4.3.2 Rearing activity. 
Previous studies have demonstrated that repeated MDMA exposure can lead to an 
increase in rearing activity, possibly due to behavioural sensitisation to the psychostimulatory 
effects (Lettfuss et al., 2013; Schenk & Bradbury, 2015). In the current study there was a 
significant effect of exposure on rearing activity for female rats, with both MDMA and 
methylone binge exposure causing an attenuation of the drug-induced suppression of rearing 
activity. There was no effect of pre-exposure on rearing by male rats for either drug. Therefore 
it seems that female rats are more susceptible to behavioural sensitisation than male rats, which 
is likely related to their higher sensitivity to the stimulatory effects of the psychostimulants. 
This is consistent with previous reports demonstrating higher sensitisation of female rats to the 
pscyhostimulating effects of MDMA following repeated exposure (Walker et al., 2007).  
Alternatively, the disinhibition of rearing activity seen in female rats following repeated 
exposure may be due to reduced stereotypic or serotonin syndrome behaviours. The most 
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frequently documented neurochemical change following repeated administration is 5-HT 
depletion (Green et al., 2003; Jones et al., 2010). It seems reasonable to suggest that this would 
cause a reduction in serotonin syndrome or stereotypic behaviours, which may lead to an 
increase in goal-oriented exploratory behaviours. Therefore the increased rearing activity seen 
in female rats may be a combination of 5-HT depletion causing tolerance to the serotonergic 
effects, and neuroplastic changes in DA neurotransmission in the NAc causing sensitisation to 
the stimulant effects (Schenk, 2011). 
These findings indicate that greater neuroplastic or neurotransmitter changes occur in 
females from the subacute exposure to MDMA, which could mean that they are at greater risk 
of long term psychological and neurocognitive sequelae from drug use. For this reason the 
importance of including both male and female participants in studies on psychostimulant drugs 
is emphasised. 
4.3.3 Light/dark box test 
The previous literature regarding tolerance or sensitisation to the anxiogenic effects of 
MDMA after repeated administration is sparse, but suggests that there may be development of 
tolerance possibly due to the 5-HT depleting effects of MDMA (Bull et al., 2004; Jones et al., 
2010). The current study found that there was a significant reduction in time spent in the light 
side of a light/dark box and a significant reduction in the number of transitions after pre-
exposure to MDMA or methylone. This effect was unlikely to be due to a habituation or 
repeated testing effect since saline controls showed no differences between trials. There was 
no effect of pre-exposure on emergence latency, contrary to the findings by Jones et al. (2010), 
suggesting that there was no change in baseline anxiety levels. 
Following exposure to MDMA and methylone there was a significant reduction in time 
spent in the light side of the light/dark box, which contrasts with the acute effects in drug naïve 
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animals as previously described. Pre-exposure had the opposite effect on transitions, reducing 
the previously seen increase in transitions after acute exposure back to the level of saline treated 
control rats. After acute exposure it was argued that the failure of these drugs to attenuate time 
spent in the light side of the chamber or transitions may have been due to the psychostimulant 
action of these drugs, resulting in non-goal directed ambulation about all areas of the light/dark 
box. Thus, the drug effects on anxiety would not be detected using these parameters since they 
are confounded by psychomotor behaviour (Bourin & Hascoet, 2003). However, following 
binge dosing it is possible that there was a tolerance to the stereotypic behaviour produced by 
these drugs, and the reduction in time spent in the light side of the box may actually be a result 
of the anxiogenic properties of these drugs. Therefore, while there was no tolerance or 
sensitisation to the quantity of ambulation as seen in the open filed, it is possible that there was 
a change in the quality of locomotion with less stereotypical behaviours, possibly via reduction 
in dopaminergic D2 receptor stimulation (Koulchitsky et al., 2016). A closer examination of 
stereotypic behaviour caused by MDMA and methylone may have provided further support to 
this theory, and should be taken into consideration in future studies examining the behavioural 
effects of these psychostimulant drugs. Overall, previous exposure to both drugs was able to 
alter the subsequent behaviour in the light/dark box, with a significant reduction in time spent 
in the light, and attenuation of the drugs effect on transitions, indicative of anxiogenesis. 
These findings support the idea that both MDMA and methylone cause anxiety in low 
doses, but do not provide any evidence for a tolerance to this anxiogenic response following 
repeated drug exposure, since there was no change in emergence latency. The reasons for the 
lack of tolerance seen in the current study may be for similar reasons as the failure to 
demonstrate sensitisation to the locomotor effects, explained previously. Whether or not these 
drugs can cause tolerance in their anxiogenic effects remains largely unknown. Given the 
importance of anxiety in the development of drug abuse and dependence, further research 
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should be conducted to determine if there is a reduction in this effect from chronic drug 
exposure. 
 
4.4 Temperature, Toxicity, and Rat Strain 
Temperature changes in the acute administration of amphetamine derivatives is 
important as acute hyperthermia has been closely correlated to the degree of serotonergic 
neurotoxicity caused by MDMA in the rat, although the ability of MDMA to cause 
neurotoxicity in humans is controversial (Docherty & Green, 2010; O'Loinsigh et al., 2001). 
Even so, hyperthermia has also been thought to play a crucial role in MDMA lethality (Green 
et al., 2003; Koenig et al., 2005). 
Previous studies have demonstrated hyperthermia for both MDMA and methylone 
following acute exposure to these drugs (Baumann et al., 2012; den Hollander et al., 2013; 
Green et al., 2003). The current study found that MDMA caused a significant and marked rise 
in temperature with repeated administration, but there was no effect on temperature for 
methylone. The mean rise in temperature for MDMA was 2.3oC and peaked at three hours after 
the first dose of MDMA, and it is possible that it would have continued to increase further if 
recording had continued. The hyperthermic effect seen in the current study is similar to those 
previously reported in male Sprague-Dawley, Dark Agouti, and Wistar rats (Green et al., 2003). 
There was no significant rise in temperature for methylone treated rats, which is contrary to 
previous findings. The reason for this may be related to the doses used in the current experiment 
which were much lower than in previous studies (Baumann et al., 2012; den Hollander et al., 
2013). Regardless, the current study demonstrates that the effect of MDMA on hyperthermia 
is much more prominent that the effect of methylone, and may therefore have a much greater 
risk in terms of toxicity. 
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There were six unexpected fatalities from 12 to 15mg/kg MDMA in the current study, 
all occurring in male rats. This was surprising given that previous studies have used comparable 
doses of MDMA in other male rat strains, including Sprague-Dawley and Wistar rats, without 
fatalities (Kalivas et al., 1998; O'Loinsigh et al., 2001). In addition, the LD50 for male rats was 
calculated using probit maximum likely hood estimation which gave an approximate LD50 of 
16.14 mg/kg (i.p.), which is much lower than the 49 mg/kg (i.p.) which has previously been 
reported for male Sprague-Dawley rats (Hardman et al., 1973). PVG/c hooded rats used in the 
current study may therefore be more susceptible to the acute toxic effects of MDMA.  
Alternatively, the high lethality of MDMA seen in these rats may be partially explained 
by aggregation toxicity. Ho et al. (2004) injected group-housed male Wistar rats with 15 mg/kg 
i.p. which resulted in fatality in 14 of the 17 rats. The authors concluded that the high fatality 
rate seen may have at least partly been due to these rats being group-housed during acute drug 
administration, given that O’Loinsigh et al. (2001) administered a higher dose of 20 mg/kg i.p. 
in this same rat strain in singly housed rats with no fatalities (Ho et al., 2004). Indeed, both 
social interaction and high ambient temperature, conditions that mimic those in which humans 
often consume MDMA, have been found to potentiate the vasoconstricitve effects and fatality 
in Long Evans rats (Kiyatkin et al., 2014). The current study group housed rats during the binge 
dosing procedure, and this may have contributed to the high rate of fatalities seen. This finding 
is important in terms of human drug use, as users of MDMA often do so in close social 
environments and often seek closer contact with others due to the drugs enactogenic effects. 
This may enhance the subjective effects as well as the toxicity of the drug. 
Male humans and rodents may be more sensitive than females to the acute toxic effects 
and hyperthermia related fatalities from MDMA (Fonsart et al., 2008; Koenig et al., 2005). The 
current findings support this hypothesis. Therefore, while the acute behavioural 
psychostimulant effects are more pronounced in female rats, the acute toxic effects of MDMA 
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are greater in males. This finding has important implications for male human users of MDMA, 
and may partly explain why there was a 4:1 (male/female) sex ratio in the number of fatalities 
associated with this drug previously reported (Schifano, 2004). This sexual dimorphism again 
highlights the importance in using both male and female animals in studying the effects of 
drugs.  
 
4.5. Implications of the Current Findings 
4.5.1 Addiction 
The potency of a drug to block the DAT or to enhance dopaminergic neurotransmission 
is associated with its psychostimulant effect and abuse liability (Rothman & Baumann, 2003, 
2006). Alternatively, drugs that increase 5-HT are not abused and increased 5-HT relative to 
DA activity may actually reduce the addictive potential of the drug (Rothman & Baumann, 
2006; Wee et al., 2005). It has been found that, in MDMA self-administration paradigms, 
MDMA is a weak-to-moderate reinforcer with only a subset of rats acquiring self-
administration (Bradbury et al., 2014; Cole & Sumnall, 2003b). Rats that fail to acquire self-
administration tend to have greater 5-HT overflow, suggesting that 5-HT may limit the 
positively reinforcing effects of MDMA (Bradbury et al., 2014). Alternatively, increased 
locomotor activity may directly relate to DA activity in the NAc, and therefore the reinforcing 
and addictive properties of psychostimulant drugs (Bubar et al., 2004; Gatch et al., 2013).  
Previous studies have shown that methylone produces elevations in DA and 5-HT 
quantitatively similar to MDMA, but with a diminished capacity to release 5-HT relative to 
DA and reduced overall potency (Baumann et al., 2012; Simmler et al., 2013). The finding that 
methylone produced greater locomotor activity than MDMA confirms that this drug has greater 
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relative action on dopaminergic neurotransmission, and may therefore have a higher abuse 
potential. In agreement with this, previous studies have found that methylone produces dose-
dependent IV self-administration through spontaneous acquisition procedures, and appears to 
produce more robust self-administration acquisition than comparable studies using MDMA 
(Nguyen, Grant, Creehan, Vandewater, & Taffe, 2016; Schenk et al., 2007; Watterson et al., 
2012). In addition, escalation of methylone intake in extended accesses self-administration was 
greater than that for rats trained to self-administer MDMA, demonstrating higher abuse 
potential (Nguyen et al., 2016; Vandewater, Creehan, & Taffe, 2015). However, self-
administration of methylone increased less than cocaine and methamphetamine, suggesting 
that the reinforcing properties of methylone are weaker, and that the potential for compulsive 
use in humans is less likely, than these primarily dopaminergic psychostimulants (Nguyen et 
al., 2016; Watterson et al., 2012). 
4.5.2 Safety and toxicity 
The current study demonstrated that MDMA can produce fatalities in male rats in doses 
as low as 12 mg/kg. However, allometric scaling of effective and toxic doses of MDMA from 
animals to humans is complex since differences in metabolism and formation of toxic 
metabolites differ among animal species (de la Torre & Farre, 2004). In addition, the route of 
administration in the current study (i.p.) is different to that of human users (oral), which has 
been shown to dramatically affect the plasma concentrations and production of toxic 
metabolites (Baumann et al., 2009). Finally, the context in which the drug is taken appears to 
be important for its toxic potential, given that aggregation toxicity has been previously 
demonstrated (Kiyatkin et al., 2014). Therefore, although previous studies have attempted to 
translate toxic and neurotoxic doses in rats or mice to humans, such estimates are probably 
inaccurate (Green, King, Shortall, & Fone, 2012), which places greater importance on human 
pre-clinical studies. What can be concluded from the current study is that MDMA is more toxic 
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and may produce greater neurotoxicity than methylone at equivalent doses in this breed of rat, 
given the hyperthermic response and fatalities produced by MDMA. Whether this translates to 
human users is unknown. Rats may be a reasonable model for examining the neurotoxic effects 
of MDMA since it is known to produce serotonin depletion consistent with findings in humans 
and other primates (Green et al., 2003). 
It is important to remember that the amount of methylone or MDMA in tablets bought 
on the streets vary widely, and many of these pills are likely to contain multiple psychoactive 
chemicals (Brunt et al., 2016). A recent study in the UK found that the mean amount of MDMA 
in one tablet was close to 60mg. However, there was wide variability, with a bimodal 
distribution of content between 20-40 mg and 60-80mg (Wood et al., 2011). This disparity in 
drug concentrations emphasises the importance of the potential harms associated with 
“ecstasy” use, and the need for more vigorous drug testing of street drugs in order to provide 
safety information and education to the public, and to track which other chemicals are being 
found in these illicit drugs. 
4.5.3 Sex differences 
The current findings are consistent with previous reports that MDMA produces greater 
psychomotor effects in females (Palenicek et al., 2005; Walker et al., 2007), and extends the 
literature with evidence that methylone also has a greater stimulant effect on females. While 
there was no difference between males and females in the reduction in rearing activity 
following acute drug exposure, there was an attenuation of MDMA and methylone suppressed 
rearing in female rats following binge dosing. This may be due to increased behavioural 
sensitisation to the drugs in female rats, or due to the reduction in stereotypic or serotonin 
syndrome related behaviours following binge exposure. Enhanced sensitisation in female but 
not male rats following repeated MDMA exposure has been previously demonstrated (Walker 
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et al., 2007). This means that female rats may have a higher degree of neuroplastic changes 
following drug exposure. 
Amphetamine-induced psychopathology has been related to the progressive 
sensitisation of locomotor effects following repeated exposure (Kalivas et al., 1998). Therefore, 
the findings of enhanced stimulant effects and sensitisation for females is important as it may 
mean that human female users of MDMA and methylone may experience greater acute and 
chronic adverse neuropsychiatric effects, especially since females tend to weigh less than males 
but consume the same size tablets (Palenicek et al., 2005). Indeed, women have been reported 
to show stronger responses to MDMA in the clinical setting, with significantly higher ratings 
for both positive and negative effects (Liechti et al., 2001). Even though no clinical studies 
have been performed on humans using methylone, it is expected that there would be a similar 
pattern of sex differences from the current findings. 
On the other hand, male rats were more sensitive to the acute toxic effects of MDMA, 
with lethality at 12 and 15mg/kg. Therefore, although females may be more sensitive to the 
psychostimulant properties of MDMA, males may be more at risk of acute toxicity and death. 
This may partly explain the higher incidence of death reported in male users of MDMA 
(Schifano, 2004).  
These findings highlight the importance of including both male and female animals in 
pre-clinical studies of drugs of abuse, particularly given the current predominance of male bias 
in neuroscience and behavioural pharmacological research and the consistent findings of sex 






The current research found evidence of an anxiogenic response to the acute 
administration of both MDMA and methylone. While there was no significant difference in 
time spent in the light side of the box and an increase in transitions in drug-naïve rats, there 
was a significant reduction in time spent in the light side of the box and attenuation of the 
number of transitions after binge-dosing. This may be interpreted in one of two ways; either 
MDMA and methylone only produced increased anxiety after repeated exposure, or MDMA 
and methylone also produced anxiety after the initial acute exposure, but expression of this 
response in the LDB was confounded by the psychomotor and stereotypic behaviours induced 
by these drugs. The second explanation seems more feasible, given that numerous previous 
studies have demonstrated anxiogenic effects from both acute and chronic MDMA exposure. 
Thus, it appears from the current findings that both MDMA and methylone exposure can 
produce anxiety-like behaviour. This is consistent with findings in studies using human 
participants, who have been shown to score higher on indices of anxiety (Kuypers, Wingen, & 
Ramaekers, 2008), and suggests that methylone may have a similar subjective effect on anxiety 
in human users. This is important given the number of emergency department admission for 
panic attacks and anxiety related behaviours such as paranoia that have been reported in the 
literature after consumption of MDMA (Liechti, Kunz, & Kupferschmidt, 2005), and suggests 
that methylone may carry an equivalent public health liability in this regard. 
4.5.5 Memory and cognitive problems 
It has been previously reported that acute MDMA administration may cause a 
temporary impairment in working and visuospatial memory in humans (Kuypers & Ramaekers, 
2005, 2007; Kuypers et al., 2008), although non-mnemonic causes for these deficits cannot be 
ruled out. Previous studies in animals have suggested that the memory impairments seen in the 
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eight-arm radial maze may be due to impaired reference memory with relative preservation of 
working memory (Harper, 2013; Harper et al., 2006; Kay et al., 2010). The current study failed 
to demonstrate any impairment in working memory for MDMA and methylone using the NOR 
task, even at high doses of either drug that would be largely in excess of doses typically used 
by humans, and therefore supports the idea that the deficits in memory seen in animal studies 
may be due to a specific impairment in reference memory. Deficits in working memory seen 
with acute intoxication in humans may therefore be a function of a more global deficit in 
neurocognitive functioning or due to non-mnemonic factors that have not been accounted for, 
rather than a specific working memory impairment. 
 
4.6 Limitations of the Current Study 
There were several limitations to the current study worth mentioning. Firstly, the doses 
of MDMA used in this breed of rat was too high, given that there were several deaths. This 
meant that the number of rats for each conditions was reduced, particularly in the binge-dosing 
experiments, with a reduction in statistical power. This was the first study to use PVG/c hooded 
rats in behavioural studies using MDMA and methylone. The doses used were based on 
previous similar studies using other rat strains (Kindlundh-Hogberg et al., 2007; McCreary et 
al., 1999; Rodsiri et al., 2011), and it was unanticipated that this strain of rat would be more 
susceptible to the acute toxic effects of MDMA. This highlights the importance of differences 
between strains and species of animal in their pharmacokinetics and metabolism of drugs. Lab 
animals often receive doses of drugs which are much higher than those taken recreationally by 
humans and by routes of administration that are not typical of human consumption (Baumann 
2008). While allometric scaling is difficult, it is clear that the MDMA dose of 12mg/kg is far 
higher than that used by recreational users since it caused substantial lethality. 
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The binge dosing procedure used in the current experiment was unable to cause 
behavioural sensitisation that has been previously observed. This may have been due to the 
short binge dosing period used, which was only two days. Previous research has demonstrated 
that three to five days of daily or twice daily dosing is generally required in order to produce 
behavioural sensitisation (Schenk & Bradbury, 2015). Alternatively it may have been due to 
the short latency period between the last dose and behavioural testing. Behavioural sensitisation 
has been shown to generally take more than twelve days to develop following the last dose 
(Kalivas et al., 1998), while in the current study behavioural testing occurred after one week. 
It is possible that if we had waited for two weeks we may have seen more behavioural changes 
following binge dosing. Future research should take these parameters into consideration when 
designing tests for tolerance and sensitisation to psychostimulants. 
Another limitation is that the behavioural tests for anxiety, including time in the centre 
of the open field, rearing activity, and the LDB, may have been confounded by the psychomotor 
stimulation or stereotypic behaviours produced by each of these drugs. In the LDB the number 
of transitions has traditionally been attributed to changes in anxiety (Bourin & Hascoet, 2003), 
while in the current study the increase in transitions may have been due to a general increase 
in locomotor activity. Time spent in the light side of the box and central ambulation in the open 
field could both be influenced by the onset of stereotypic, or non-goal directed, behaviours 
which have been demonstrated previously in MDMA treated rats (O'Loinsigh et al., 2001). In 
addition, rearing behaviour may have been reduced by serotonin syndrome behaviours such as 
low body posture as previously suggested (Palenicek et al., 2005; Spanos & Yamamoto, 1989). 
Thus it would have been beneficial to measure the stereotypic and serotonin syndrome 
behaviours for both MDMA and methylone so that they could be accounted for when 
interpreting this behavioural data. Secondly, since psychomotor stimulation and stereotypic 
ambulation could confound the results in the LDB and EPM these tests of anxiety may not be 
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appropriate for MDMA and methylone, and this may be the reason why previous studies have 
found conflicting results in terms of anxiolysis or anxiogenesis for MDMA in high doses 
(Ferraz-de-Paula et al., 2011; Lin et al., 1998). Future research using these drugs should 
carefully measure stereotypic behaviours in order to determine whether observed behaviours 
are truly due to the cognitive processes that they intend to measure, or whether they are 
confounded by the onset of aimless repetitive behaviours. 
Finally, there is a lot of individual variability in the response to MDMA in human users, 
particularly at higher doses (Baylen & Rosenberg, 2006; Downing, 1986; Harris et al., 2002). 
This was also evident in the current study since the standard error in observations increased 
proportionately with increasing doses of both MDMA and methylone. This implies that the 
behaviour of the rats became less predictable at higher doses, which may have been a function 
of individual idiosyncratic differences between animals, and reduced the power to make 
statistically significant findings. It may be possible to stratify animals based on prior 
behaviours in order to predict individual traits, and therefore account for this when performing 
statistical analysis. For example, Ludwig et al. (2008) divided Wistar rats into high anxiety or 
low anxiety sub-groups based on their behaviour in an EPM screening test, and found that 
behavioural sensitisation and reduction in anxiety was more pronounced for low anxiety rats 
following multiple daily injections of MDMA (Ludwig, Mihov, & Schwarting, 2008). Thus 
identification and consideration of individual differences in rats may allow researchers to make 
more accurate predictions of subsequent behaviour. 
 
4.7 Future Research 
There are several important considerations from the current study that should be 
addressed in future research. To begin with, the current study only looked at the acute 
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behavioural effects and development of tolerance or sensitisation from subacute dosing of 
MDMA and methylone. With increasing widespread abuse of psychostimulant drugs, more 
research is needed investigating the acute and chronic neurocognitive effects of these drugs in 
humans and animals using a wider range of cognitive tasks. Thus, future studies should also 
look at the chronic effects of repeated administration on areas of neurocognition, such as 
memory, and neuropsychology, such as anxiety. Impairment in memory and development of 
chronic anxiety has been previously attributed to repeated MDMA exposure, so determining 
whether this is also seen in chronic methylone exposure warrants further investigation.  
The current research used PVG/c rats which have not previously been used in acute 
behavioural studies using MDMA. The doses used were consistent with previous research but 
led to a high number of fatalities. Using a consistent strain of rat for drug studies, such as 
Sprague-Dawley which has predominantly been used in previous research on MDMA, allows 
easier interpretation and comparison between studies. However, this may also lead to a rather 
facile view of the effects of these drugs. Indeed, the current study illustrated that the LD50 of 
MDMA may be strain dependent, and could therefore be more unpredictable and dangerous in 
human users than previously anticipated. In addition, there has been a predominance of using 
only male animals in neurobiological research (Beery & Zucker, 2011; Hughes, 2007b). The 
higher sensitivity of female rats to the acute effects of psychostimulants, and the higher toxicity 
seen in males, provides further evidence that sex bias in research jeopardises our understanding 
of sexual dimorphism in the effects of drugs. 
The measurement of anxiety levels in the current study was difficult since the 
development of psychomotor stimulation and stereotypic and serotonin syndrome-like 
behaviour confounded interpretation of the results. Traditionally, exploratory behaviour, time 
spent in the aversive light side of the LDB, number of transitions, and emergence latency have 
all been associated with changes in the levels of anxiety in mice and rats (Bourin & Hascoet, 
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2003; Jones et al., 2010). However, the use of these parameters in the assessment of the 
anxiogenic or anxiolytic effects of MDMA and methylone may not be reliable since they are 
confounded by the general psychomotor effects of these drugs. Previous studies using the EPM 
have demonstrated increased time in the open arms with high doses of MDMA which has been 
interpreted as anxiolysis (Ferraz-de-Paula et al., 2011; Ho et al., 2004; Palenicek et al., 2005), 
however whether these result were confounded by the same opposing behaviours as seen here 
is not known. This illustrates the importance of choosing behavioural tests wisely, while taking 
note of confounding behaviours, in order to maximise internal validity. 
From pharmacological studies alone it was predicted that methylone would have a 
behavioural response that would be approximately half that of MDMA. What was observed, 
however, was that methylone produced dose-dependent increases in locomotor activity that 
were greater than those observed with MDMA. This highlights the importance of conducting 
both neurochemical and behavioural studies in order to draw appropriate conclusions about the 
effects of drugs. In addition, the doses used in the current study were too high and caused 
multiple fatalities. Future research should aim to use doses that appropriately scale to typical 
human users in order to improve face validity. Correlation of the dose-response obtained in 
different strains and species of animal to the dose-response obtained in human pre-clinical 
studies may help in this regard. However, the legal and ethical restraints of using controlled 
substances in human subjects inhibits such progress. 
Further research investigating the nature of DA and 5-HT interactions will help our 
understanding of the complex interplay between these systems. The use of psychostimulants 
are a valuable research tool that allow us to augment neural systems and carefully observe the 
behaviours produced, which can then be correlated with the psychopharmacological effects. 
The use of monoaminergic drugs such as MDMA and methylone are important in this regard. 
For example, the onset of stereotypies by these drugs may provide useful clues to the neural 
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mechanisms that underlie conditions characterised by an excessive tendency to repetition, such 
as Tourette syndrome and obsessive-compulsive disorders, which are thought to be caused by 
abnormal dopaminergic activity (Ford, 1991). 
 
4.8 Conclusion 
Methylone is an interesting new designer psychostimulant with similar 
psychopharmacological and behavioural effects to MDMA. The current study is the first to 
directly compare behaviour after acute and subacute administration of MDMA and methylone 
in rats. We were able to show that MDMA and methylone shared similar but distinct behaviours 
in a wide range of tests. Specifically, we were able to show that methylone has greater 
psychostimulant effects than MDMA, and therefore seems to demonstrate a cocaine-MDMA-
mixed behavioural profile as previously anticipated from pharmacological studies (Simmler et 
al., 2013). This has important implications in terms of the abuse liability for methylone, and 
supports the current enforcement of control of this substance. In addition, we demonstrated that 
female rats were more susceptible to the acute stimulant effects of both drugs, while male rats 
were more sensitive to the acute toxic effects of MDMA. Thus, drugs of abuse demonstrate sex 
related differences which may have important consequences when extrapolating animal data to 
humans. Data concerning the chronic effects of MDMA and methylone are lacking, and this 
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